

6-1-2009

Mitochondrial Reactive Oxygen Species Production in Excitable Cells: Modulators of Mitochondrial and Cell Function

David F. Stowe
Marquette University

Amadou K.S. Camara
Medical College of Wisconsin

Mitochondrial Reactive Oxygen Species Production in Excitable Cells: Modulators of Mitochondrial and Cell Function

David F. Stowe

*Anesthesiology Research Laboratories, Department of Anesthesiology, Department of Physiology, Cardiovascular Research Center, The Medical College of Wisconsin
Department of Biomedical Engineering, Marquette University
Research Service, Veterans Affairs Medical Center
Milwaukee, WI*

Amadou K. S. Camara

*Anesthesiology Research Laboratories, Department of Anesthesiology,
The Medical College of Wisconsin
Milwaukee, WI*

Abstract

The mitochondrion is a major source of reactive oxygen species (ROS). Superoxide ($O_2^{\bullet-}$) is generated under specific bioenergetic conditions at several sites within the electron-transport system; most is converted to H_2O_2 inside and outside the mitochondrial matrix by superoxide dismutases. H_2O_2 is a major chemical messenger that, in low amounts and with its products, physiologically modulates cell function. The redox state and ROS scavengers largely control the emission (generation scavenging) of $O_2^{\bullet-}$. Cell ischemia, hypoxia, or toxins can result in excess $O_2^{\bullet-}$ production when the redox state is altered and the ROS scavenger systems are overwhelmed. Too much H_2O_2 can combine with Fe^{2+} complexes to form reactive ferryl species (e.g., $Fe(IV)=O^{\bullet}$). In the presence of nitric oxide (NO^{\bullet}), $O_2^{\bullet-}$ forms the reactant peroxynitrite ($ONOO^-$), and ONOOH-induced nitrosylation of proteins, DNA, and lipids can modify their structure and function. An initial increase in ROS can cause an even greater increase in ROS and allow excess mitochondrial Ca^{2+} entry, both of which are factors that induce cell apoptosis and necrosis. Approaches to reduce excess $O_2^{\bullet-}$ emission include selectively boosting the antioxidant capacity, uncoupling of oxidative phosphorylation to reduce generation of $O_2^{\bullet-}$ by inducing proton leak, and reversibly inhibiting electron transport. Mitochondrial cation channels and exchangers function to maintain matrix homeostasis and likely play a role in modulating mitochondrial function, in part by regulating $O_2^{\bullet-}$ generation. Cell-signaling pathways induced physiologically by ROS include effects on thiol groups and disulfide linkages to modify post-translationally protein structure to activate/inactivate specific kinase/phosphatase pathways. Hypoxia-inducible factors that stimulate a cascade of gene transcription may be mediated physiologically by ROS. Our knowledge of the role played by ROS and their scavenging systems in modulation of cell function and cell death has grown exponentially over the past few years, but we are still limited in how to apply this knowledge to develop its full therapeutic potential.

I. Introduction

The turn of the century has seen a resurgence of interest in mitochondrial generation of reactive oxygen species (ROS), first discovered and understood during the late 1960s and early 1970s. The renewed interest derives from the newer concept that ROS are not always deleterious to cell function and from the use of more sensitive and accurate techniques and probes to understand the mechanism of ROS generation and scavenging systems. A number of commentaries and well-researched reviews have been published since 2000 on the

putative mechanisms of ROS production and the complex pathophysiologic effects that ROS exert on cell function; many of these are referenced throughout this review (8, 27, 31, 48, 55, 59, 66, 72, 75, 80, 81, 113, 122, 126, 132, 133, 140, 146, 163, 179, 183, 189, 202, 209, 234, 241, 243, 244, 246, 299, 303, 307, 328). Many of these reviews address very specific aspects of mitochondrial bioenergetics or deal with nonmitochondrial ROS production or both. For this review, we hope to present a comprehensive understanding of mitochondrial ROS production sites and their regulation, ROS scavenging, and physiologic as well as pathologic effects of ROS, particularly as triggers of cell protection.

A. Focus of review

This review focuses primarily on the ROS generated by the mitochondrial respiratory complexes, the sites and conditions for ROS generation, cell regulation of ROS generation and ROS scavenging, cell-damaging effects of ROS vs. physiologic regulation of mitochondrial and cell function by ROS, and the emerging role of pharmacologic approaches to manipulate generation and scavenging of specific ROS. Other potential sources of ROS exist in mitochondria (*e.g.*, glycerol-3-phosphate dehydrogenase, acyl-CoA dehydrogenase), but their physiological significance remains to be elucidated (8). This report concentrates on studies of mitochondria in excitable cells with high metabolic rates (*i.e.*, mammalian myocardial and nervous system cells). Mitochondrial density is very high in muscle and nerve cells because of their higher O₂ consumption rate compared with that of most other cell types. The number, size, shape, interconnections, and location of mitochondria are also different depending on cell types (91). Mitochondria also serve different functions within the same cell [*e.g.*, in nerve cells (91) and between the interfibrillary and subsarcolemmal mitochondria in cardiac cells (213)].

This review summarizes studies on how and why ROS are generated by mitochondrial electron-transport complexes in physiologically low amounts, perhaps up to 1% or 2% of the total rate of O₂ consumption (77), to modulate mitochondrial and cell function. A number of topics are addressed: How can ROS be generated when the level of the electron acceptor O₂ is low? What is the source and

location of “good” *versus* “bad” ROS? Which are the physiologically relevant ROS, and what are their targets? How are the levels of physiologic ROS modulated? How can generation or scavenging of ROS be manipulated to support cell function when the cell is stressed? Are low O₂-induced cell signaling pathways initiated at the mitochondrial level, and does an increase or decrease in ROS mediate this activity?

This review does not specifically address the significant extramatrix and nonmitochondrial sources of ROS [*e.g.*, cytochrome *b*₅ reductase, peroxisomes, catecholamines, hydroquinones, plasma membrane oxidases such as NADPH oxidase, lipoxygenases, monoamine oxidases, xanthine/xanthine oxidase, coupled or uncoupled nitric oxide synthase, and eicosanoids pathways, among others (303)]. Most of these compounds can initially lose an electron to form the superoxide anion radical (O₂^{•-}) by autooxidation. The nonmitochondrial ROS released or formed in the cytosol are buffered generally under strong reducing conditions by intracellular thiols, particularly glutathione (GSH) and thioredoxin (TRXSH₂) by the activities of their reductases (303); this topic is addressed only as applied to mitochondriaderived ROS. The free radical NO[•] can have profound effects on mitochondrial function (*i.e.*, competing with O₂ at mitochondrial respiratory complex IV and reacting with O₂^{•-} to form peroxynitrite). The source of the NO[•] may be vascular endothelium, nerve terminals, or other cytosolic sources. Controversial evidence that suggests that NO[•] may be generated by a mitochondrial NO synthase (23, 24, 136, 137), but this review deals primarily with respiratory complex-derived O₂^{•-} and its products.

B. Ambiguities about ROS

Although much is known of the chemistry of ROS (151), much less is known about the specific molecular sites and conditions for electron leak and O₂^{•-} generation along the electron-transport pathway under pathophysiologic conditions (32, 61). Some topics addressed subsequently: How and why do singlet electrons escape during electron transfer? What are the physiologic pathways for O₂^{•-} release? How can O₂^{•-} be formed during state 3 (ADP-stimulated) respiration when the ΔΨ_m is less polarized because of the influx of protons? How can more O₂^{•-} be generated when O₂ levels decrease? Are isolated

mitochondria a proper model for assessing ROS generation? What is the relative amount of $O_2^{\bullet-}$ generated at sites along the respiratory complexes? Does $O_2^{\bullet-}$ or other ROS function as an O_2 sensor to modulate enzyme activity? What distinguishes physiologic from pathologic release of $O_2^{\bullet-}$? It is hoped that this review will furnish at least satisfactory answers to most of these questions.

II. Overview of Mitochondrial Structure and Function

A. Structure

Mitochondria are membrane-enclosed organelles (1- to 10- μ m diameter) that generate most of the cell's supply of ATP; they also have a role in cell signaling and differentiation, Ca^{2+} buffering, apoptosis and cell death, as well as control of the cell cycle and cell growth (322). Many of these processes are triggered or mediated by Ca^{2+} or ROS or both. The number of mitochondria in a cell varies widely by organism and tissue type. Many cells have only a single mitochondrion, whereas others can contain several thousand mitochondria (265, 322). Mitochondrial compartments include the outer mitochondrial membrane (OMM), the inner membrane space (IMS), the inner mitochondrial membrane (IMM), and the cristae and matrix (265). The OMM has a protein-to-phospholipid ratio similar to that of the plasma membrane ($\sim 1:1$ by weight) and contains large numbers of integral proteins called porins that form channels to allow molecules of more than 5,000 Daltons to diffuse freely across the OMM (265). Larger proteins also can enter the mitochondrion if a signaling sequence at their N-terminus binds to large multi-subunit proteins (translocases) that then actively transport them across the OMM. Disruption of the OMM permits proteins in the IMS to leak into the cytosol, leading to cell death (87). Because the OMM is freely permeable to small molecules, the concentrations of small molecules, such as ions and sugars, in the IMS is the same as in the cytosol (265). However, as large proteins must have a specific signaling sequence to be transported across the OMM, the protein composition of the IMS is different from the protein composition of the cytosol. One protein that is localized to the IMS in this way is cytochrome *c* (87).

The IMM contains proteins with several functions (225, 265): (a) redox reactions of oxidative phosphorylation, (b) ATP synthase/ATPase, (c) transport proteins that regulate metabolites across the matrix, and (d) protein-import machinery. The IMM has a 3:1 protein-to-phospholipid ratio and is rich in the phospholipid cardiolipin, which contains four fatty acids that help to make the IMM impermeable (322). Unlike the OMM, the IMM does not contain porins and is highly impermeable to all molecules, so that all ions and molecules require membrane transporters to enter or exit the matrix.

Mitochondria vary in number and location according to cell type. Liver cells have ~1,000–2,000 mitochondria per cell, making up 20% of the cell volume (2), and the IMM (+cristae) area is about 5 times greater than that of the OMM. In cardiac mitochondria, the cristae area is much larger, and mitochondrial volume can reach 30% of cell volume. Mitochondria often form a complex 3D branching network inside the cell with the cytoskeleton and tight connections to other organelles. The association with the cytoskeleton determines mitochondrial shape and function (265).

B. Function

The membrane potential across the IMM is formed by the action of the respiratory enzymes and the TCA cycle (225, 322). Each pyruvate molecule produced by glycolysis is actively transported across the IMM and into the matrix, where it is oxidized and combined with coenzyme A to form CO₂, acetyl-CoA, and NADH (322). The acetyl-CoA is the primary substrate to enter the TCA cycle. The enzymes of the TCA cycle are located in the mitochondrial matrix, with the exception of succinate dehydrogenase, which is bound to the IMM as part of complex II. The TCA cycle oxidizes the acetyl-CoA to CO₂, and, in the process, produces three molecules of NADH and one molecule of FADH₂, which are a source of electrons for transport along the respiratory complexes, and a molecule of GTP (that is readily converted to an ATP) (322). The redox energy from NADH and FADH₂ is transferred to O₂ in several steps *via* the electron transport along the respiratory complexes. The individual proteins of complexes I to V

specifically interact to form defined supramolecular structures, the so-called "respiratory supercomplexes" or "respirasome" (114).

Reducing equivalents from the cytoplasm can be imported *via* the malate-aspartate shuttle system of antiporter proteins or fed into the electron-transport system (ETS) by using a glycerol phosphate shuttle. NADH dehydrogenase, cytochrome *c* reductase, and cytochrome *c* oxidase perform the transfer, and the incremental release of energy is used to pump protons (H^+) into the IMS (322). As the proton concentration increases in the IMS, a strong electrochemical gradient is established across the IMM. The protons can return to the matrix through the ATP synthase complex, and their potential energy is used to synthesize ATP from ADP and inorganic phosphate (P_i) (322). This process, called chemiosmosis, was first described by Peter Mitchell (230), who was awarded the 1978 Nobel Prize in Chemistry for his work.

III. Mitochondrial Sources and Mechanism of ROS Generation

A. Requirement for charged membrane, electron flux, and O_2

Molecular O_2 (dioxygen) has two unpaired electrons with parallel spin in different antibonding orbitals. $O_2^{\bullet-}$ arises directly from the reduction of O_2 by transfer of a lone electron to its antibonding orbital (151). The electrons are believed to escape from the mitochondrial ETS at discrete sites during the transport of electrons (Figs. 1 and 2A) from NADH oxidoreductase (complex I) to cytochrome *c* oxidase (complex IV), the ultimate electron acceptor by which $O_2 + 4e^-$ and $4H^+$ is reduced to $2H_2O$. Oxygen, necessary for life in aerobic organisms, is therefore simply a sink for electrons (66).

The standard reduction potentials of electron carriers in the four mitochondrial complexes span the range of redox potentials from NADH at complex I (-0.32 V) to O_2 at complex IV ($+0.82$ V) (Fig. 2B). The standard reduction potential for the reduction of O_2 to $O_2^{\bullet-}$ is about -0.16 V (307), so many components of the respiratory

complexes in the ETS are thermodynamically capable of irreversibly transferring an electron to O₂. However, the single-electron transfers are tightly controlled and quickly coupled with the second electron transfer (107, 293, 294). The energy released as electrons are transferred along the respiratory chain is conserved into an H⁺ gradient directed outward through the IMM. Ejection of protons alkalinizes the matrix to create a transmembrane H⁺ electrochemical-potential gradient, the proton motive force ($\Delta\mu_{H^+}$), comprising the membrane potential ($\Delta\Psi_m$, -150 mV) and the smaller pH-gradient potential (ΔpH_m , -30 mV) (201). The energy stored in the $\Delta\mu_{H^+}$ is partially dissipated as H⁺ reenters the matrix at complex V (ATP synthase), which rotates a protein rotor to convert ADP and P_i to ATP. This process is reversible.

B. Reactive and nonreactive O₂ species and reactants

The generation of ROS from mitochondria was first reported in the early 1970s (44, 218). ROS are O₂ molecules alone or bound to elements C, H, or N in different states of oxidation or reduction (Table 1) (151). The primordial mitochondrial ROS is the free radical O₂^{•-} (Fig. 2B), which, as noted earlier, has an added unpaired electron. Although O₂^{•-} can reduce Fe³⁺ to Fe²⁺ and react with other ligands to form other radicals, its usual fate is rapid dismutation ($K_d=1.6 \times 10^9\text{M/s}$) to hydrogen peroxide (H₂O₂) by superoxide dismutase (SOD) in the mitochondrial matrix (MnSOD) and IMS and cytosol (CuZnSOD). During the dismutation reaction, the O₂^{•-} is first protonated to the hydroperoxyl radical (HO₂[•]) ($K_d 10 \times 10^7\text{M/s}$), and two HO₂[•] react ($K_d 9 \times 10^5\text{M/s}$) to form H₂O₂ and H₂O (151). Thus, the spontaneous dismutation rate of HO₂[•] is ~100 times faster than that of O₂^{•-} and because it is uncharged, HO₂[•], unlike O₂^{•-}, can cross membranes (104). With a pK_a of 4.8 for the HO₂[•]/O₂^{•-} pair, very little O₂^{•-} exists as the protonated form in the mitochondrial matrix. It follows that dismutation of O₂^{•-} to H₂O₂ occurs faster when the matrix pH is lower ($k=5 \times 10^5\text{M/s}$ at pH 7.0 and 10^2M/s at pH 11) (151).

Not all ROS are actually free radicals (e.g., H₂O₂ and peroxynitrite, ONOO⁻) (Fig. 3). When a free radical reacts with a nonradical, the product is another free radical, whereas the interaction of two free radicals produces a nonradical (151). For example, ONOO⁻

is a nonradical formed from the interaction of NO^\bullet and $\text{O}_2^{\bullet-}$. ONOO^- is stable at an alkaline pH and fairly nonreactive, but ONOO^- is readily protonated (cytosol more than matrix) at cellular pH to ONOOH (peroxynitrous acid), which is very cytotoxic, like HO^\bullet , and causes depletion of $-\text{SH}$ groups and other antioxidants, oxidation of lipids, DNA strand breakage, as well as nitration of and deamination of DNA bases, especially guanine (151). H_2O_2 is not a free radical and is not so strong an oxidant as $\text{O}_2^{\bullet-}$, and H_2O_2 , like H_2O , diffuses more easily through aquaporins than through lipid membranes (37, 38). H_2O_2 is normally maintained at low levels by catalase and glutathione peroxidase, among others, which convert H_2O_2 to H_2O and O_2 .

H_2O_2 also can participate in the one-electron reaction with transition metal ions (*e.g.*, Fe^{2+} bound to organic molecules) to generate various intermediate ferryl species (274, 275), such as Fe(IV)=O^\bullet , a powerful oxidizing agent that can lead to lipid oxidation and DNA damage, as discussed in section VI. The rate constant, k , for reactions of Fe^{2+} is very dependent on the ligand attached to the iron (*e.g.*, it is 2 times greater for Fe^{2+} -ADP than for Fe^{2+} -ATP). Ferryl species exist only in a complex and are produced at their site-specific targets in DNA, proteins, and lipids. Other much slower reactants of H_2O_2 produced are $\text{Fe(III)+OH}^\bullet$ (Fenton reaction); this reaction is 30 times slower than that of ferryl compounds with H_2O_2 , so the hydroxyl radical (HO^\bullet) is formed in very small amounts and has no specific reactivity with biomolecules (144). ONOO^- is also a stable oxidant that, in its protonated form, ONOOH , can produce oxidative changes in lipids, proteins, carbohydrates, and nucleic acids. Thus, although $\text{O}_2^{\bullet-}$ and NO^\bullet are the initial free radicals, H_2O_2 rather than $\text{O}_2^{\bullet-}$ is mostly regarded as the relevant biologically active metabolite.

C. Assessing ROS generation

The measurement of the various ROS is dependent on suitable techniques to assess levels of ROS. The technique should not directly produce ROS or produce artifacts. Preferably the technique should directly measure intra- *versus* extramatrix generation of $\text{O}_2^{\bullet-}$. The most direct and selective approach to measure specific ROS, notably in the matrix, is to use electron paramagnetic resonance (EPR) (16, 129, 151). EPR is based on absorption of microwave radiation stimulated by

an electromagnetic field in molecules such as free radicals and transition metal ions with unpaired electrons. Adsorption of microwave energy creates two distinct energy levels from the unpaired electrons as they transition from a lower state to a higher state. The number of unpaired electrons present in a sample is proportional to the amplitude of the ESR signal (111). Only stable ROS that accumulate to measurable levels can be identified directly at biologic temperatures, so either extreme cooling or spin traps, which involve reaction of the radical with an adduct that is stable, is used. Examples of EPR signals are shown in Fig. 4.

The majority of recent studies on mitochondrial ROS production use either the intramatrix fluorescence indicators 2',7'-dichlorofluorescein (DCF) or the fluorescent Amplex Red/horseradish peroxidase technique to assess H₂O₂ that is released or converted in the buffer ("cytosol") surrounding the mitochondria or both. Figure 5 shows typical recordings of the rate of accumulation (slope) of H₂O₂ by the latter technique. Because of the high catalytic activities of MnSOD and CuZnSOD, most O₂^{•-} is rapidly converted to H₂O₂, which is readily permeable to the IMM. Therefore, the measurement of intra- *versus* extramatrix-generated O₂^{•-} is indirect and incomplete because of its rapid dismutation to H₂O₂ and the sidedness (intra- or extramatrix) of O₂^{•-} release.

In isolated tissue, other options exist to assess ROS. One is the shift in absorbance with reduction of cytochrome *c* by O₂^{•-}; other techniques are based on release of photons by chemiluminescence probes, such as luminol or lucigenin, on reaction with ROS (111). Dihydroethidium (DHE), also known as hydroethidium (HE), is a rather specific fluorescent marker for O₂^{•-}. O₂^{•-} nonenzymatically converts DHE to 2-hydroxyethidium (2-OH-E⁺) or a precursor (331), which appears to be rapidly made, is labile, and fluoresces at a slightly shorter wavelength (more red) than the heme-peroxidase oxidation product ethidium that can intercalate to bound with DNA. Thus, the 2-OH-E⁺ signals fluctuate with the O₂^{•-} generated in the cell, as now shown in many studies by using spectrophotometry (5, 70, 71, 181, 182, 247, 269, 271, 298, 316, 317). Figure 6 displays a typical recording of O₂^{•-} assessed by DHE fluorescence in intact hearts. Note the dynamic effects of changing temperature in the presence and

absence of drugs. Caution in the use of DHE (and other probes) lies in its oxidation to ethidium by cytochrome *c* in the absence of ROS (33). Because the DHE product is altered by drugs that act on the mitochondrion (71), it is assumed that mitochondria are the major source of $O_2^{\bullet-}$ by this method in isolated tissue. A derivative of DHE is MitoSOX Red, which has a phosphonium group that selectively targets and enters mitochondria in response to the negative membrane potential; thus, imaging of the signal in cells indicates a mitochondrial source of $O_2^{\bullet-}$ (273).

Another method that depends on the interaction of $O_2^{\bullet-}$ and NO^{\bullet} is the formation of dityrosine from tyrosine by $ONOO^-$ (29); Fig. 7 shows an example of the dynamic changes in dityrosine formation in intact hearts during a change in temperature and drug treatment. It is assumed that the induced shift in wavelength, assessed with spectrometry, is an extracellular indicator of $ONOO^-$ (71, 247, 248). Nitration of tyrosine (no color) by $ONOO^-$ to 3-nitrotyrosine (yellow color) is another indicator of reactive nitrogen species usually identified in proteins (151).

D. Sites and conditions for mitochondrial ROS generation

The specific molecular sites of electron leak are not known with certainty, but a great deal of intense investigation has led to sites within complexes I and III (Figs. 1 and 2A). Specific mitochondrial inhibitors (64, 197) (Table 2) are typically used to (a) force electrons to leak outside of the very tight single-electron transfer mechanism (*e.g.*, antimycin A) leading to $O_2^{\bullet-}$, or (b) to block electron leak (*e.g.*, stigmatellin or rotenone) with glutamate as substrate. For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256). In the presence of glutamate, the inhibitors rotenone, antimycin A, and stigmatellin can each increase ROS. However, in the presence of succinate as substrate, antimycin A can increase, whereas both stigmatellin and rotenone can decrease ROS (255, 256). Thus, the possible pathways have been identified primarily with substrates and inhibitors by using deductive reasoning, with the understanding that the mechanism of

electron leak may be quite different in a more-relevant pathophysiologic situation.

E. Complex I (NADH ubiquinone oxidoreductase)

This transmembrane complex (Fig. 1) oxidizes NADH [reduced from the transfer of electrons and H⁺ from tricarboxylic acid (TCA) intermediates], uses coenzyme Q₁₀ (ubiquinone, Q) as the electron acceptor and is coupled (as are complexes III and IV) with proton pumping, thus contributing to the proton motive force, $\Delta\mu\text{H}^+$. The actual mechanism of proton pumping is almost completely unknown, in part to the large size of complex I and the difficulty in measuring the intermediates in the coupling reaction (201). Complex I is one of two major sites of entry for reducing equivalents; the other is complex II, succinate dehydrogenase (more precisely known as succinate ubiquinone oxidoreductase) (Figs. 1 and 2). Succinate (and α -glycerophosphate transferred from the cytosol to the matrix by the glycerol phosphate shuttle) alone reduces FAD to FADH₂, and each molecule furnishes two electrons to the respiratory chain, as do pyruvate and TCA-cycle intermediates isocitrate, α -ketoglutarate, and malate, by reducing NAD⁺ to NADH.

Complex I is probably the major source of mitochondrial ROS under most physiologic conditions (335). Exogenous quinones can enhance ROS generation from isolated complex I (65). Inhibitors of complex I are useful for determining the source of ROS (96, 252). Several sites between the Flavin complex and the quinone site have been proposed to generate O₂^{•-} within complex I (77, 134, 160, 199, 216, 320). One or more of the Fe-S centers is a likely source (135, 160, 251), although the ubisemiquinone (QH[•]) binding site (143, 160, 200), or the flavin complex (216), *per se*, could also be sources, as depicted in Fig. 8. It has been proposed that complex I has two redox active nucleotide-binding sites; the F site is the location for electron entry for the NADH oxidation by Q, and coupled translocation of 4 H⁺ for each NADH oxidized; the R site is where electrons exit during the succinate-supported NAD⁺ reduction, which is O₂^{•-} generating (321).

When mitochondria oxidize succinate alone (lacking other TCA substrates), the energy of the $\Delta\mu\text{H}^+$ is used to transfer electrons

against the redox potentials of the electron carriers from reduced coenzyme Q (quinol, QH₂) to NAD⁺, rather than forward to the final electron acceptor O₂ (Fig. 9). This is called reverse electron transfer. Interestingly, a high transmatrix pH gradient appears to contribute more than the $\Delta\Psi_m$ to O₂^{•-} generation with succinate as the substrate (Fig. 10) (201). It was suggested that the Δ pH-sensitive O₂^{•-} generation is mechanistically linked to proton pumping at complex I (201). When electrons are transferred backward from complex II (22, 158, 307), this creates the largest source of O₂^{•-} as a percentage of O₂ consumption, although this does not likely occur *in vivo*. Reverse and forward electron flow is believed to contribute to an H₂O₂-production rate of ~400 and 50 pmol/min/mg protein, respectively (256).

Reverse electron transfer requires a large $\Delta\Psi_m$ or Δ pH; this occurs as electrons are passed to NAD⁺ until the pool is fully reduced to NADH. O₂^{•-} generation by this mechanism ceases or decreases if the mitochondria are (a) uncoupled by a proton ionophore (*e.g.*, CCCP), (b) generating ATP during state 3 respiration, or (c) leaking protons into the matrix (matrix acidification or uncoupling proteins). Rotenone (Table 2), an irreversible inhibitor of electron transfer from the ubiquinone (Q) binding site to complex I, prevents reverse electron transfer and ceases O₂^{•-} release by this mechanism. This implies that O₂^{•-} is generated between the rotenone binding site and NAD⁺ in complex I. The physiological importance of succinate only-induced O₂^{•-} generation by reverse electron transfer is dubious (335). However, because succinate is a TCA-cycle intermediate, it along with NADH-linked substrates likely contributes to O₂^{•-} generation during electron transfer *in vivo*, particularly if electron flow is impeded. It was reported that succinate concentration-dependent H₂O₂ generation was only slightly reduced in the presence of NADH-linked substrates (335) (*i.e.*, succinate-induced H₂O₂ production occurred under conditions of regular downward electron flow in complex I). Because NADH-linked oxidation was progressively decreased, but not abolished, by increasing succinate concentration, it was proposed that the two substrates compete for electron delivery to complex III, with succinate "pushing" electrons toward and NADH-linked substrates away from complex I (335). In this way, succinate concentration may modulate the rate of H₂O₂ release by controlling the QH[•]/Q₂ ratio.

For forward electron transfer, it is postulated that the electrons from NADH-linked substrates (*e.g.*, pyruvate) are moved to ubiquinone Q *via* the flavin complex and Fe-S centers to form QH[•], and in a second step that is linked to a low ΔpH , to form QH₂ (200). In the absence of rotenone, NAD⁺-linked substrates can also enhance O₂^{•-} generation at complex I if the $\Delta\Psi_m$ is higher than normal (8); this condition of forward electron flow is favored by a high degree of reduction of the redox carriers proximal to the complex I proton pump. Once in a high redox state, QH[•] can lose its unpaired electron to O₂ as all upstream redox centers are fully reduced (200). Moreover, if the ΔpH is large, QH[•] is longer lasting, and more O₂^{•-} may be formed. It is not known whether complex I has a Q cycle (231) like complex III (200). O₂^{•-} is believed to be released only on the matrix side of the IMM at complex I (200, 256, 295).

F. Complex III (co-enzyme Q, bc₁ complex, ubiquinone/cytochrome c reductase)

This complex (Fig. 11) is believed to contain a Q cycle with an inner (Q_i) and outer (Q_o) pool of ubiquinone (Q) facing the matrix (i) and the intermembrane space (o) (42, 43, 97–99, 211, 268, 295, 296, 307, 308). Evidence for the Q cycle (231) arose when it was reported that addition of O₂ to anaerobic mitochondria caused a transient reduction of cytochrome *b* rather than an expected oxidation; this suggested that at least two different sites for electron transfer existed (43). In the subsequent model, QH[•] is believed to form at both the Q_i and Q_o sites. First, ubiquinone (Q) is fully reduced to QH₂ in the inner side of the IMM and migrates to the outer side, releasing 2 H⁺ and transferring one electron to cytochrome *c*₁ (Rieske Fe-S protein) to form the first QH[•] and Q (the electron moves on to cytochrome *c* and cytochrome *c* oxidase (complex IV)). The second electron reduces cytochrome *b* so that electrons are moved from Q at the Q_o site to the Q_i site, and Q is reduced to QH₂, completing the cycle. Cytochrome *c* and cytochrome *c* oxidase accept only single electrons in sequence. Thus, the complete reduction of Q at the Q_i site requires that the Q_o site must oxidize two QH₂ molecules in two successive turnovers. This powers the complex III proton pumps, but the second bifurcation reaction cannot occur unless the first does (138). Rather than transfer an electron to cytochrome *c*₁, the prolonged lifetime of QH[•] is believed

then to allow it to undergo autooxidation by releasing a singlet electron to be attacked by O_2 , forming $O_2^{\bullet-}$.

Myxothiazol is a complex III inhibitor (296) that binds at the Q_o site of the Q pool to block electron transfer from QH_2 at site Q_o to Fe-S clusters and to cytochrome b_2 (Table 2, Fig. 11). Stigmatellin blocks transfer of the first electron to the Fe-S center (center P, QH_2 oxidation site Q_o) (96). Antimycin A binds to the Q_i site to block electron transfer of the second electron to the Q_i site. Thus, antimycin A stimulates electron leak by inhibiting QH_2 formation (center N, Q reduction site) so that Q^{\bullet} accumulates at the Q_o site, whereas myxothiazol prevents formation of Q^{\bullet} at the Q_o site (Fig. 11). The finding that antimycin A did not affect H_2O_2 generation when added after myxothiazol indicated that myxothiazol stimulates H_2O_2 generation at a site in the Q_o center proximal to the site that is inhibited by antimycin A (296). Myxothiazol and stigmatellin inhibit the ROS-inducing effect of antimycin A, as noted earlier. The QH^{\bullet} radical is fleeting and highly reactive and is not readily detected (320).

These studies suggested that $O_2^{\bullet-}$ generated at complex III would be released into the IMS rather than into the matrix space. Evidence for this was found in mitoplasts devoid of the OMM (152). This would further suggest that CuZnSOD is responsible for converting $O_2^{\bullet-}$ to H_2O_2 in the cytosolic space and that MnSOD would not have much importance for protecting the matrix from ROS damage. However, the Q_i site can also be a site for ROS generation, particularly with limited electron transfer into the Q_o center of complex III (263). Moreover, the MnSOD (matrix SOD) gene knockout is lethal (204, 214), whereas the CuZnSOD (extramatrix SOD) gene knockout is not, although the life span is shortened (118), and oxidative stress is elevated by twofold to threefold (235). This indicates the importance of high MnSOD activity to convert $O_2^{\bullet-}$ to H_2O_2 , which unlike $O_2^{\bullet-}$, can easily exit the matrix. The relative amounts and conditions for ROS generated by complex III on either side of the IMM that play a physiologic role remains to be resolved. This information will be important because the balance between antioxidant capacities and $O_2^{\bullet-}$ generation within and outside the matrix that contribute to overall ROS emission is not clear.

Most studies indicate that ROS are generated, especially at complex I, during state 4, when the redox state and $\Delta\Psi_m$ are high (Fig. 12), but not during state 3 (ADP phosphorylation). In the presence of succinate plus rotenone, $O_2^{\bullet-}$ can be generated by forward electron transfer *via* complex III, although at much lower rates than for reverse electron transfer with succinate alone, as noted earlier. This too requires a high redox state. However, it is possible to observe enhanced ROS at complex III with pyruvate/malate or succinate/rotenone during state 3 conditions (276) (high respiration, ATP synthesis, slightly decreased redox state, and $\Delta\Psi_m$) when O_2 availability is high (Fig. 13) or protein concentration is low (276), or when complex I is blocked with rotenone (199) (Fig. 14) and antimycin A is given to block the Q_i site (308). It is not known how substantial ROS are formed pathophysiologically (*i.e.*, hypoxia) if state 3 conditions are maintained, but small amounts of ROS clearly can initiate protective pathways, as discussed in sections VII and VIII.

IV. Pathologic Induction of Mitochondrial ROS Release

Tissue damage during hypoxia and reperfusion after ischemia has long been known to be associated with increased levels of various ROS (6, 15, 19, 123, 170, 290, 309, 318). Reperfusion after ischemia increases markers of ROS. Administration of scavengers of $O_2^{\bullet-}$ and H_2O_2 , but not of $O_2^{\bullet-}$ alone, reduces the extent of injury (70). Isolated hearts exhibit a hypothermia-dependent linear increase in both $O_2^{\bullet-}$ (Figs. 6 and 15) and $ONOO^-$ (Fig. 7) (71). Although nonmitochondrial sources of ROS exist during ischemia [*e.g.*, NAD(P)H oxidase (141, 188, 328) and xanthine oxidase (25) in vasculature], the majority of ROS are likely derived from the mitochondrial respiratory complexes, as shown by the damage to respiratory complexes (212, 213, 245) and the effect of mitochondrial inhibitors (5, 28, 71, 81–86). The increase in H_2O_2 generation in mitochondria isolated after cardiac ischemia/reperfusion injury was enhanced by either rotenone or antimycin A (84); this suggested that both complexes I [Q and/or N_2 (final) Fe-S center] and III were damaged and capable of producing $O_2^{\bullet-}$ after ischemia/reperfusion injury. The source of $O_2^{\bullet-}$ generation during cell hypoxia leans toward complex III, in part because a decrease in oxidant stress during hypoxia in cytochrome *c*-null cells mimics the actions of myxothiazol and

stigmatellin (145, 146), which in effect prevent electron transfer to cytochrome *c* (Fig. 11). Loss of cytochrome *c* locks the Rieske Fe-S complex and cytochrome *c*₁ in a reduced state and prevents oxidation of QH₂ by the Fe-S complex to QH[•] (145, 146).

A. ROS-induced ROS release

In addition to induction of ROS by hypoxia, ischemia, hypothermia, and mitochondrial toxins, ROS *per se* may lead to even greater ROS generation in a self-amplifying manner (46, 336). Photoexcitation of individual cardiac myocyte mitochondria caused an initial slow increase in ROS that culminated in a large burst of ROS (Fig. 16) that accompanied an abrupt loss of $\Delta\Psi_m$ and opening of the mitochondrial permeability transition (MPT) pore (336). This phenomenon, called ROS-induced ROS release (336), may be associated with Ca²⁺ overload and may play a role in initiating apoptosis, but whether normal stimuli initiate it is not known. It seems unlikely that Ca²⁺ overload can itself induce ROS generation because it dissipates $\Delta\Psi_m$ and reduces the redox state; but it may hinder the ROS scavenger system so that more ROS are liberated (8). During early ischemia in isolated hearts, ROS increase along with mitochondrial [Ca²⁺] and the redox state (NADH), as shown in Fig. 17 (5, 70, 298), and treatment with exogenous intra and extramatrix ROS scavengers reduces ROS and mitochondrial [Ca²⁺] and better maintains the redox state (NADH) on reperfusion after ischemia, as exemplified in Fig. 18 (70).

Another example is ROS generated by cytosolic NAD(P)H oxidase in a loop with ROS generation by mitochondria and then again by NAD(P)H oxidase (112). In this recent study, it was found that angiotensin II led to mitochondrial dysfunction by activating vascular NAD(P)H oxidase *via* a protein kinase C (PKC)-dependent pathway. The O₂^{•-} produced by NAD(P)H oxidase appeared to increase mitochondrial O₂^{•-} generation as well as to decrease NO[•] bioavailability. Moreover, the H₂O₂ generated by mitochondria was proposed to cause a feed-forward activation of more O₂^{•-} by further activating NAD(P)H oxidase (112).

B. ROS-induced Ca²⁺ loading

Because ischemia and hypoxia are marked in the cell not only by ROS release but also by Ca²⁺ loading, it is not clear whether one leads to the other or whether they are completely independent events (11). Again, it seems unlikely that increased Ca²⁺ can induce O₂^{•-} generation because it can also induce MPT pore opening to abolish ΔΨ_m (59, 297). Ca²⁺-transport systems are sensitive to redox conditions, so damage to Ca²⁺ import and export systems by ROS is more likely to lead to Ca²⁺ overloading (72). Moreover, ROS-triggered MPT pore opening is potentiated by Ca²⁺ overload (59). Nevertheless, it has been postulated that Ca²⁺ can induce ROS physiologically (59), a topic discussed in more detail in section VIII.

An effect of cytochrome *c* release during MPT pore opening and rupture of the OMM is the activation of caspase proteases. The collapse of ΔΨ_m does not occur before these caspases are activated and released (267), and cytochrome *c* may function to shunt any free electrons released outside the matrix to complex IV, thus initially reducing O₂^{•-} generation (8). Activated caspase-3 can disrupt electron transfer at complexes I and III (but not at complex IV) to induce O₂^{•-} generation as a feed-forward pathway, leading to the collapse of ΔΨ_m and initiation of apoptosis (267). This is discussed in more detail in section VII.

C. ROS generation during tissue ischemia and hypoxia

During the last decade, it has become increasingly clear that ROS are produced not only during reperfusion and reoxygenation after ischemia or hypoxia, but also during ischemia (Figs. 17–19) (5, 28, 70, 181–183, 247, 269, 270, 298, 317) and hypoxia (316). Figures 17 through 19 show examples of ROS fluctuations during ischemia and reperfusion during conditions of ischemia preconditioning, ROS scavenging, and hypothermia in isolated hearts. This seemingly paradoxical situation of ROS emission during ischemia (145, 146) can be explained because cells never truly become anoxic, and so O₂ remains available to form O₂^{•-} radicals (78). The rate of O₂^{•-} generation is chemically proportional by mass action to the O₂ concentration times the rate of electron leak (310), but in isolated liver mitochondria, an

[O₂] >50 μM does not alone result in greater O₂^{•-} generation, as shown in Fig. 20 (161). Mitochondria can respire normally at a very low *p*_{O₂}; only when *p*_{O₂} decreases to <5–7 torr does respiration begin to be limited by the O₂ supply (80). The K_m for O₂ of cytochrome *c* oxidase is <1 μM, and mitochondrial function is independent of a *p*_{O₂} down to <2 torr. If O₂ levels are forced to decrease toward zero, electron transfer (respiration) through the respiratory complexes becomes markedly slowed, and the electron carriers operate at a more reduced state. How this occurs is not known, but it has been proposed (145, 146) that if the gene for cytochrome *c* expression were deleted, this would prevent cytochrome *c*₁ from giving up its electron at that site, and in turn, at the Reiske Fe-S protein site and in QH₂ at the Q_o site, so that the QH[•] radical, and thus O₂^{•-} would not be generated, and these sites would remain locked in a reduced state.

During conditions of blocked electron transfer *via* the respiratory complexes and a highly reduced redox state (5, 70, 298), the QH[•] radical may exist too long or be incapable of full reduction to QH₂ because of changes in protein conformation (61, 146, 221), so that electrons leak to combine with O₂ in a thermodynamically favorable reaction. Other possibilities are that a low [O₂] at complex IV leads to cytochrome *c* reduction and so limits its capability to scavenge O₂^{•-} (63, 292), and that access of QH[•] to O₂ is improved at low O₂ levels (146).

*D. Very low *p*_{O₂} and lack of mitochondrial ROS generation*

Despite the accumulating evidence that ROS are indeed formed during ischemia and hypoxia, and mostly from the mitochondrial respiratory complexes, a recent direct study refutes that hypoxia enhances ROS. In recent, detailed experiments on this apparent paradox (161), it was demonstrated in liver mitochondria that between 20 and 200 μM O₂ concentration, respiration, H₂O₂ generation, and cytochromes *a/a*₃ redox state were unchanged; the H₂O₂ production rate was lower during state 3 than during state 4. Below 20 μM, [O₂] respiration and H₂O₂ generation (Fig. 20), both decreased toward zero, and the cytochromes *a/a*₃ redox state became more reduced. It was of interest, however, that H₂O₂ generation as a *percentage* of the

respiratory rate increased fourfold (state 4) and sixfold (state 3) from 20 μM to near zero $[\text{O}_2]$. It was concluded (161) that (a) hypoxia in intact cells may elicit ROS from nonmitochondrial sources, (b) probes used are not specific for ROS, (c) cytosolic pathways are required for low O_2 sensing and ROS generation, (d) inhibition of complex IV by NO^\bullet is required, (e) a hypoxia-induced decrease in total release of ROS downregulates signaling pathways involved with ROS, and (f) the fractional increase in ROS generation as a percentage of respiration acts as a hypoxia signal. It is, moreover, possible that hypoxia and ischemia produce derangements in mitochondrial electron transfer because of changes in substrate utilization (*e.g.*, succinate) and redox state that lead to generation of $\text{O}_2^{\bullet-}$ independent of the effect of a reduced $[\text{O}_2]$ to accept electrons at complex IV.

Endogenous NO^\bullet modulates respiration by its effect to compete reversibly for the O_2 binding site on cytochrome *c* oxidase (complex IV) (45, 58, 119). In endothelial cells, blocking the effect of NO^\bullet to compete for O_2 at complex IV with an NOS inhibitor enhanced the rate of O_2 consumption (respiration) at very low O_2 concentrations (89). This indicated that NO^\bullet inhibition of O_2 binding might be responsible for the inability of mitochondria to consume O_2 readily at low O_2 concentrations. Endothelial cells are a natural source of NO^\bullet , and NO^\bullet may be generated in mitochondria (137, 139), and with $\text{O}_2^{\bullet-}$, to produce ONOO^- (and ONOOH), which can modulate cell function, as addressed in section III. However, whether the enzyme NO^\bullet synthase actually resides in the IMM is very controversial (54, 302).

Obviously, much work remains to be done to understand why, how, and from where ROS are generated in isolated cell or organ systems during hypoxia or ischemia but apparently not in isolated hypoxic mitochondria (161) without the use of electron-transport inhibitors. It is not known whether the ratio of $\text{O}_2^{\bullet-}$ generated from complex I and from the Q_i versus Q_o sites changes during hypoxia and reoxygenation or during ischemia and reperfusion, and how the activities of MnSOD versus CuZnSOD and other cellular antioxidant systems modulate the emission (generated minus scavenged) of distinct ROS. The specific sites, sidedness, relative amounts of $\text{O}_2^{\bullet-}$ generation, and its products in these complexes remain to be elucidated. It is possible that the source of $\text{O}_2^{\bullet-}$ generation and the

particular kinds and amounts of ROS change during the course of ischemia and reperfusion, as suggested by the observed time-dependent phasic changes in NADH and FAD redox state, mitochondrial $[Ca^{2+}]$, and $O_2^{\bullet-}$ levels (DHE, ETH) during ischemia (examples shown in Figs. 17 through 19) in isolated heart studies (5, 7, 70, 181, 183, 269, 298). Note, for example, in Fig. 19, that MnTBAP, given during brief ischemic pulses before the longer ischemic period, reversed the marked decrease in ROS during late ischemia and reperfusion induced by ischemia preconditioning (IPC), suggesting that $O_2^{\bullet-}$ is required to initiate IPC.

V. Antioxidant Defenses Against Pathologic ROS Formation

A. SODs, catalase, cytochrome c, GSH, and TRXSH₂, and other linked redox couples

Cellular antioxidant defenses depend on the reduction potential of the electron carriers and the reducing capacity of linked redox couples in the matrix (NADH/NAD⁺ and FADH₂/FAD) and cytoplasm (10). Severe cell stress can induce ROS formation that exceeds the capacity of antioxidant enzymes, so that the net emission of ROS is increased. Up to a limit, mitochondrial and cell antioxidant systems are capable of neutralizing excess ROS. These include the intra- and extramatrix SODs (171, 263), and glutathione (GSH) (253, 279) and thioredoxin (TRXSH₂) (171) systems (Fig. 21), catalase in the cytosol, and cytochrome c in the intermembrane space (discussed in section VII). GSH, a tripeptide with the thiol (-SH) group of cysteine as the active site, is an abundant source of reducing equivalents; it reduces phospholipid hydroperoxides (PHPs) and H₂O₂, among other peroxides, *via* PHP glutathione peroxidase, an enzyme essential for life (8). GSH peroxidase, TRXSH₂, and TRXSH₂ reductase gene knockouts are also embryonically lethal (234). GSH and TRXSH₂ are maintained in a highly reduced state by their reductases; this allows them to reduce effectively H₂O₂ and lipid peroxides to H₂O. The resulting oxidized forms, GSSG (glutathione disulfide) and TRXSS (thioredoxin disulfide), rely on the NAD(P)H/NAD(P)⁺ redox state to again become reduced.

Thus, efficient mitochondrial bioenergetic function is required for the antioxidant activity of these systems.

B. Regulation of genes encoding mitochondrial antioxidant systems

The activities of antioxidant redox pairs do not appear to be constant. For example, a transcriptional coactivator, (PPAR)- γ coactivator 1- α (PGC-1 α), a major regulator of oxidative metabolism and mitochondrial biogenesis, is believed to regulate the mitochondrial antioxidant defense system (153, 312). Endothelial cells that overexpressed PGC-1 α upregulated the activity of oxidative stress-protective genes (mRNA for MnSOD, Prx3, Prx, TRXSH₂, TRXSH₂ reductase, UCP-2, and catalase) and resulted in reduced accumulation of ROS, increased $\Delta\Psi_m$, and reduced apoptotic cell death. This work (312) indicates that increased mitochondrial demand for energy production is met by activation of PGC-1 α , which also enhances the mitochondrial antioxidant defenses.

C. ROS generation versus ROS scavenging

Normally, mitochondria likely serve as a net sink rather than a net source of ROS because of these very efficient scavenger systems (8), but ROS release can become excessive. During ischemia, O₂^{•-} and H₂O₂ levels increase as antioxidant defenses are overwhelmed and complex oxygen intermediates are formed (77, 240). One effect of an excessive initial release of ROS could be more ROS formation by ROS-induced ROS release by a mechanism that may involve MPT pore opening (336) or by caspase-induced modification of respiratory complexes during initiation of apoptosis (267). A high cytosolic GSH/GSSG ratio indicates a large reducing capacity to detoxify ROS and prevent activation of innermembrane anion channels (IMACs), which precedes MPT pore opening (10). The overabundance of ROS during Ca²⁺ overload with a collapsed $\Delta\Psi_m$ could reflect more the inability of the GSH, Pr-SGG, and TRXSH₂ systems to regenerate the reduced state (thus less H₂O₂ removal) than of more ROS to be generated (8).

Superoxide, as a charged species, is relatively impermeable to membranes but can pass through anion (*e.g.*, IMAC) channels (11, 152). NO[•] is not ionized and so is much more membrane permeable and can compete for O₂^{•-} with SOD to produce the nonradical ONOO⁻ (29), which protonates at a low pH to ONOOH, which is highly reactive to tissues. NO[•] can also react with O₂ to form nitrogen dioxide, NO₂[•] (brown gas pollutant). The fate of O₂^{•-} (depending on NO[•] availability) is typically dismutation to H₂O₂, which can then be converted to H₂O by catalase or to site-directed metal radicals [*e.g.*, (Fe=O)²⁺] in the presence of transition metals bound within numerous organic molecules. It is the stable and membrane-permeable H₂O₂ that is the most abundant reactant that, in excess, likely leads to damage to cell structure and function *via* these ferryl reactants.

Because “good” ROS are regulators or modulators of normal cell function, it is difficult to draw the line on which ROS effects or amounts are beneficial and which are deleterious. The so-called diverse, non-receptor mediated, “bad” effects of ROS are mentioned here, but arbitrarily. It must be emphasized that the net effect of ROS is dependent not only on how much was produced, but also more important, on how much was not inactivated by antioxidant defenses. Thus, the generegulated GSH/GSSG, TRXSH₂/TRXSS, and Pr-SSG/PrSH redox system, as well as other scavengers that play important roles in protection against excess ROS-induced injury, are the same factors that probably modulate physiologic ROS signaling.

D. MPT pore opening and cytochrome c

Inhibition of MPT pore opening with cyclosporin A could prevent loss of the carrier cytochrome *c* so that an e⁻ is normally transferred to complex IV from cytochrome *c*₁, and QH[•] is oxidized to Q rather than O₂ being reduced to O₂^{•-}. As discussed also in section VII, MPT pore opening with release of oxidized [Fe(III)] cytochrome *c*, an O₂^{•-} scavenger, may reduce ROS emission in the IMS by oxidizing O₂^{•-}. Inhibiting MPT pore opening may also prevent the loss of enzyme scavengers of ROS within the matrix that normally neutralizes ROS in the matrix (220). The independence or interrelation of matrix and extramatrix ROS release and scavenging and Ca²⁺ loading with MPT pore opening remains unclear.

VI. Targets of Excess ROS Emission

A. DNA, proteins, and phospholipids

A sensitive target of excess ROS is mitochondrial DNA (Fig. 22), which is subject to an oxidation rate 10- to 20-fold higher than that of nuclear DNA (140, 142, 262). This is due in part to the lack of histone protection and the proximity to the ETS. For example, ROS intermediates can react with desoxyguanosine to form 8-hydroxydesoxyguanosine (288), which over time interferes with DNA duplication and RNA replication (125, 140). Mitochondrial proteins are also subject to attack by ROS (88, 121, 157, 257, 318). ROS can damage TCA-cycle enzymes, especially aconitase and α -ketoglutarate dehydrogenase (62, 168, 249, 250, 277). Other damaging effects of ROS are on the respiratory complexes, most at complex I and least at complex IV (66). Amino acids are also subject to oxidizing attack by ROS, and the GSH, TRXSH₂ and other redox systems are important not only for neutralizing ROS but also for repairing damage due to oxidation of proteins by virtue of their thiol groups (189). Protein oxidation can lead to unfolding and result in loss of catalytic function and degradation (289) [e.g., ROS can damage the Na/K ATPase complex (287)].

Phospholipids are major targets of ROS (48); Transition metal radicals like (Fe=O)²⁺ can initiate lipid peroxidation cascades in membranes to generate a complex mixture of short-chain aldehydes (Fig. 23), many of which are believed to be toxic. Accumulated ROS damage with aging may damage the lipid composition required for complex I activity. It was found (319) that liver mitochondria of old *versus* young rats showed a decrease in respiratory rate and reduced activity of complex I but not complex III. It was postulated that an increase in somatic mtDNA mutations would affect the hydrophobic subunits of complex I that are essential for CoQ binding and energy conservation, or that age-related defects of complex I, such as direct alterations of the protein or lipid environment, particularly cardiolipin, which is required for complex I activity, may play a role.

B. Role of cardiolipin

Cardiolipin is a phospholipid found only in the IMM that anchors the mobile electron carrier cytochrome *c* to the IMM and optimizes the activity of electron-transport complexes, especially complex IV. Cardiolipin can be especially damaged by ROS because of these important roles (213, 258, 260, 261). Submitochondrial particles that exhibit loss of cardiolipin and cytochrome *c* during ischemia exhibit enhanced H₂O₂ release (83), which suggests their importance in protection against ROS. Excess ROS are primarily accountable for initiating MPT pore opening with the subsequent swelling, OMM rupture, and release of cytochrome *c* (187) and feedback generation of ROS (336). Accumulation of ROS over time is believed to be wholly or partially responsible for aging (210), but recently this has been questioned for vertebrates (234).

VII. Approaches to Reduce Excess ROS

A. Capacity of mitochondrial and cell reductants

From the foregoing material, it is evident that, to decrease ROS-mediated cell damage, MPT pore opening (35, 109, 110), and apoptosis due to hypoxia, ischemia, or toxins, one could attempt either to reduce the ROS generation or to enhance ROS scavenging so that overall ROS emission is diminished. Maintaining a large pool of reductants (like the GSH system) requires bioenergetically stable mitochondria to regenerate the reduced state after detoxifying the ROS. Supplying exogenous GSH may be protective but only if sufficient NAD(P)H is also available. Other cytosolic and matrix antioxidant systems exist, as described in section V. The endogenous mechanism of PGC-1 α -mediated activation of redox cycling systems also was discussed in section V.

Chance *et al.* (77) proposed antioxidant capability must be found near sites of ROS production. An antioxidant mechanism, located at the site of electron transfer to complex IV and generation of O₂^{•-} in complex III, is carried out by cytochrome *c*. Cytochrome *c* can accept or donate an electron, depending on the valence of its heme (Fe) state. It was shown that adding exogenous cytochrome *c* to

cytochrome *c*-depleted mitochondria reduced $O_2^{\bullet-}$ levels by sevenfold to eightfold (325, 332). In its reduced form (Fe^{2+}), cytochrome *c* normally generates a proton motive force ($\Delta\mu H^+$) during its oxidation by cytochrome *c* oxidase (complex IV), as one O_2 molecule is fully reduced to two molecules of H_2O by addition of $4e^-$ (8, 332). In its oxidized form [Fe^{3+} , or $Fe(III)$], cytochrome *c* forms O_2 and Fe^{2+} by virtue of the reducing ability (e^- donation) of $O_2^{\bullet-}$ with $Fe(III)$, thus neutralizing superoxide. Interestingly, Fe^{2+} cytochrome *c*, but not $Fe(III)$ cytochrome *c*, can suppress H_2O_2 levels by giving an e^- to H_2O_2 to form H_2O (332, 333). This is called the "alternative electron-leak pathway," (*i.e.*, reduction of preexisting H_2O_2 to H_2O by reduced cytochrome *c*). This mechanism can balance e^- leak to O_2 (forming $O_2^{\bullet-}$) with an e^- leak to H_2O_2 (forming H_2O) and so function to protect against too much ROS formation.

Because $Fe(III)$ cytochrome *c* is a very efficient scavenger of $O_2^{\bullet-}$ within the matrix, when $Fe(III)$ cytochrome *c* is released into the IMS during MPT pore opening and initiation of apoptotic signaling, it could act as an ideal extramatrix antioxidant (292). However, the loss of cytochrome *c* to the IMS may allow matrix $O_2^{\bullet-}$ to increase because of an absence of cytochrome *c* (220).

B. Exogenous SODs and catalase

Treatment with superoxide dismutases and catalase is another approach. However, effective delivery of these enzymes into the cytosol and matrix as a therapy is quite problematic. Overexpression of these enzyme systems could be successful in enhancing antioxidant defenses, but because ROS also play a significant physiologic role (described later), the effects may be deleterious, as indicated by a six- to 10-fold overexpression of MnSOD, which caused reduced fertility and abnormal development in mice (264), and the lack of any benefit to prolonging life span in mice overexpressing CuZnSOD (166). However, overexpression of catalase localized to mitochondria increased median life span in mice by 5 months (280). We reported that administration of the chemical SOD mimetic MnTBAP alone actually worsened cardiac function after ischemia in isolated hearts, whereas addition of glutathione and catalase with MnTBAP elicited the best protection (70); Fig. 18 shows the changes in ROS and

mitochondrial Ca^{2+} during and after ischemia with these treatments. Our study suggested that enhanced generation of matrix $\text{O}_2^{\bullet-}$ during ischemia must be coupled with its dismutation to H_2O_2 and its oxidation to H_2O to offer the best protection.

C. Proton leak to modulate superoxide generation

Another perhaps more practical approach is to modify mitochondrial bioenergetics in a way that leads to reduced capability for producing $\text{O}_2^{\bullet-}$. As discussed earlier, it may be possible to generate $\text{O}_2^{\bullet-}$ during state 3 or when $\Delta\Psi_m$ is less polarized (291, 276, 324), but most experimental studies show that even a slight decrease in $\Delta\Psi_m$ (191, 201, 324) or transmatrix ΔpH (201) results in marked reduction or cessation of ROS production. Therefore, temporary partial uncoupling of respiration from phosphorylation by inducing an extrinsic proton "leak" may be therapeutic. Essentially, this process short-circuits the gated passage of H^+ through complex V to make ATP, so that respiration increases at the expense of no gain in phosphorylation (mild uncoupling) (47, 49, 60). It takes a greater electron-transfer rate to maintain the $\Delta\Psi_m$ when an H^+ leak is present. Oxidative phosphorylation is not wholly efficient, as up to 25% of basal H^+ flux into the matrix could be outside of complex V, as suggested by the heat produced as a fraction of the standard metabolic rate (Fig. 24) (55). The net effect of H^+ leak is to stimulate respiration (electron transfer) and produce heat at the expense of ADP phosphorylation.

H^+ leak is maximal when $\Delta\Psi_m$ is highly polarized, and little or no leak occurs when ATP is being generated. In vitro, state 4 respiration occurs only when no substrate ADP exists, ATP is not being consumed, or complex V is blocked (oligomycin). Thus, H^+ leak may be an intrinsic mechanism to attenuate electron leak and $\text{O}_2^{\bullet-}$ generation when the $\Delta\Psi_m$ is large. At a high $\Delta\Psi_m$ with a greater probability to generate $\text{O}_2^{\bullet-}$, the maximal capability to have a proton leak would tend to decrease $\Delta\Psi_m$ and thus $\text{O}_2^{\bullet-}$. The mechanism of basal H^+ leak is unknown but is thought to be protonophoric (*i.e.*, H^+ is carried across the IMM) (55). H^+ leak is assessed indirectly by any increase in respiratory rate or decrease in $\Delta\Psi_m$ or both during inhibition of complex V (Fig. 25).

D. Uncoupling proteins

A small class of "uncoupling" proteins, called UCPs 1–4, are believed to induce an inward proton "leak" in charged mitochondria (49, 55, 176, 300). AMP may also act allosterically on adenine nucleotide translocase (aka adenine nucleotide transporter, ANT; or ADP, ATP carrier, AAC) to induce an H⁺ leak (67). Proton leak could also be elicited by cycling of protonated/unprotonated nonesterified fatty acids (Fig. 24) (55, 132, 175), and by repetitive gating of the MPT pore by protons (53, 169). It is feasible that UCPs and AMP could play a role in protecting against ischemia and reperfusion injury, particularly if they could be activated or stimulated before the insult to reduce $\Delta\Psi_m$ and before the redox state increases because of inhibited electron transfer. Mitochondria isolated from perfused rat hearts subject to ischemic preconditioning had a greater H⁺ leak than did ischemia controls (Fig. 25) (238); this H⁺ leak was completely abolished by the UCP inhibitor GDP, or by the ANT inhibitor carboxyatractyloside (CAT) (238). ATP also inhibits UCPs (174). However, ANT, rather than UCP2, may be most responsible for the antioxidant mechanism in heart muscle mitochondria (238). It was suggested (238) that the smaller H⁺ leak induced by ischemic preconditioning is mediated by UCP, because the H⁺ leak in ischemia controls was blocked only weakly by GDP, but strongly by CAT, whereas the larger leak in ischemia/reperfusion alone is mediated by ANT.

E. HNE-induced proton leak

Some lipid peroxidation products, such as 4-hydroxy-*trans*-2-noneal (HNE) may induce partial uncoupling of mitochondria through UCPs and are thought to initiate protective mechanisms (41, 116). HNE can also induce uncoupling of oxidative phosphorylation by enhancing H⁺ leak through other membrane proteins such as ANT if $\Delta\Psi_m$ is high (14). This H⁺ leak, although preventable by CAT, did not interfere with ANT inhibition (14), so it was suggested that HNE causes a conformation change in ANT. Although ROS can activate UCPs (117) and ROS and HNE can directly cause a small proton leak (55), whether UCPs are activated by either endogenous ROS or HNE has been rigorously questioned (75). Because ubiquinone (Q) is not required for

activation of UCPs (174), it is unlikely that ROS from complexes I or III exert a significant role. Together these studies indicate that mild uncoupling by H⁺ leak reduces ROS formation in state 4 and that UCPs can induce a small H⁺ leak, but evidence that mitochondrial ROS activate UCPs and the UCPs mediate protection against ROS-induced cell damage is not yet convincing.

It remains unclear how free fatty acids and alkenals like HNE activate proteins such as UCPs and ANT (14). One possibility is that a protonated fatty acid may cross the IMM into the matrix and dissociate, while the fatty acid anion is translocated back out of the matrix by the protein. Flip-flopping of the protonated and unprotonated forms would cause a net flux of H⁺ into the matrix; other mechanisms are proposed (14). For alkenals (nonfatty acids), it was proposed recently that H⁺ conductance *via* ANT occurs by formation of covalent adducts only at a high $\Delta\Psi_m$, thereby exposing sulfhydryl groups and lysine residues to attack by alkenals and causing a conformation change in ANT. This was based on the finding that CAT blocked H⁺ leak *via* ANT if given before but not after HNE, whereas blockade of the ANT transport mechanism remained; this that implied HNE caused a permanent conformational change in ANT distinct from its translocation role (14).

F. ROS-induced proton leak

Brookes (55) proposed that ROS and H⁺ leak comprise a loop not requiring UCPs to operate, but rather that the leak is dependent on the $\Delta\Psi_m$ alone. A high $\Delta\Psi_m$ would generate ROS (191), and the ROS would in turn induce an H⁺ leak to reduce the $\Delta\Psi_m$ in a feedback manner. The generated O₂^{•-} could induce an H⁺ leak indirectly through a lipid oxidation product or possibly *via* protonation of O₂^{•-} in the acidic intermembrane space to HO₂[•] (215), which is membrane permeable and is deprotonated in the alkaline matrix (104). A decrease in the phosphorylation to respiration (P/O) ratio (*i.e.*, uncoupling), may come at the expense of higher $\Delta\Psi_m$ and ROS. The higher, but less efficient, metabolic rate associated with H⁺ leak may be linked to the aging process (55). ROS could cause an H⁺ "slip" rather than an H⁺ leak. H⁺ slip is described as direct reduction of cytochrome *c* by the O₂^{•-} generated into the intermembrane space, thereby bypassing the

Q_i site (55), as discussed earlier in this section. Instead of 8H⁺ pumped per 4e⁻ at complex III, only 4H⁺ would be pumped per 4e⁻; this effectively represents a 50% reduction in ATP synthesis capacity at a given level of respiration.

VIII. Physiologic Modulation of Mitochondrial ROS Emission

A. H₂O₂ and ONOO⁻ as chemical effectors

Despite rather efficient electron transfer along the respiratory system (*i.e.*, little electron leak), one might ponder why the mitochondrion and its surrounding environment are incapable of removing all the ROS that are produced despite the well-developed and necessary scavenging systems. Or one could argue that natural selection allowed a system that uses ROS for cell signaling and even protection against damage. Although the mitochondrion is largely a sink for O₂⁻ and H₂O₂ due to its ROS scavenger systems, it likely releases small amounts of H₂O₂ as a natural chemical messenger in the modulation of mitochondrial and cellular function (27, 113, 126, 183, 203, 206). It was noted that the MnSOD knockout is lethal (204, 214), that MnSOD overexpression is associated with developmental abnormalities (264), and that ROS are required to trigger the apoptotic mechanism (68, 172, 207, 323), which is useful to actively eliminate poorly functioning cells and is required during embryonic development. It is now well known that ROS trigger or mediate ischemic and pharmacologic preconditioning of hearts (15, 27, 102, 181, 183, 248, 254, 303). However, it is difficult to determine how much, from where, and what kind of ROS is beneficial *versus* detrimental. Although a therapeutic goal may be to reduce ROS emission, particularly during oxidative stress, too much scavenging or the wrong kind of scavenging may eradicate protective cell signaling mechanisms, as we have shown (70) and several reviews (118, 163, 203, 235, 303) have suggested.

The complex and extensive scavenging systems, the ROS/H⁺ leak-feedback relation, and the possible role of UCPs in H⁺ leak are several selected areas of research in which attempts have been made to understand the pathophysiologic regulation of ROS emission. It is evident that the bioenergetics state of mitochondria is important, not

only for generation of ROS but also for ROS scavenging, and therefore the regulation of ROS emission. For example, free fatty acids function as natural mild uncouplers by preventing the transmembrane electrochemical H^+ potential difference (ΔmH^+) from being above a threshold critical for ROS formation by complexes I, III, or both (190).

NO^* , a well-known modulator of cell function, is not reviewed in detail here because its generation within mitochondria is debatable, as mentioned in section IV. However, the interaction of NO^* and $O_2^{\bullet-}$ to form $ONOO^-$ and $ONOOH$ as cell-toxic NO^* derivatives is well known; but low concentrations of $ONOO^-$ (0.1mM) were found to protect neurons against NO^* -mediated apoptosis by activating the phosphoinositide-3-kinase (PI3K)/Akt antiapoptotic signaling pathway (106). The activation was accompanied by an increase in oxidized phosphoinositide phosphatase (PTEN), indicating that activation of PI3K/Akt inhibited PTEN and the NO^* -mediated apoptotic pathway. $ONOO^-$ also was shown to stimulate pentose phosphate pathway (PPP) activity and the accumulation of NADPH, an essential cofactor for glutathione regeneration, and to activate glucose-6-phosphate dehydrogenase (G6PD), an enzyme that catalyzes the first rate-limiting step in the PPP (128). These and other studies [reviewed in (39)] indicate that low levels of $ONOO^-$, like low levels of H_2O_2 , have a potential cytoprotective effect that could be explored therapeutically.

B. ROS modulation by cations

An additional area of focus recently is the role of cation exchangers and channels in modulating ROS and cell signaling. In developing the chemiosmotic theory of energy coupling, Mitchell (229) recognized that mechanisms must exist to exchange anions for OH^- and cations for H^+ in the IMM; otherwise, in creating the $\Delta\Psi_m$, the mitochondrion would swell and lyse, as only cations could leak in and anions leak out. Thus, mitochondrial cation antiporters (exchangers) were found to be necessary to regulate an osmotic differential across the IMM that would result from the high H^+ electrochemical gradient (34, 131). The chemiosmotic hypothesis requires several electroneutral cation antiporters for H^+ (NHE, Na^+/H^+ exchanger; and KHE, K^+/H^+ exchanger) and a low permeability to K^+ and Na^+ (34, 131, 239). In this way, counterions to H^+ would enter and leave the

matrix along their electrochemical gradients, thus preventing osmotic swelling. Modulation of extramatrix and matrix pH affects the protonation of $O_2^{\bullet-}$ and $ONOO^-$, as discussed in section III.

C. K^+ : A modulator of ROS generation?

The K^+ cycle (Fig. 26) is believed to be an important element in modulating mitochondrial function (34, 130, 131, 133) and may modulate ROS release (9, 159). The importance of regulated pathways for both K^+ uptake and K^+ efflux may be that this flux regulates a very fine tuning of mitochondrial volume that affects the rate of respiration (149, 150). K^+ may be taken up *via* one or more putative mitochondrial K^+ channels on a stimulus of low ATP levels or increased Ca^{2+} (K_{ATP} , K_{Ca}). In isolated cardiomyocytes, it was reported that increases in ROS and NO^{\bullet} are downstream effects of application of a drug thought to open K_{ATP} channels (205), but we have found it difficult to observe significant increases in ROS with pharmacologic preconditioning agents, including K^+ channel openers and anesthetics in isolated hearts (182, 183, 298). Figure 27 (from ref. 182) shows a small increase in ROS (ETH) in isolated hearts exposed to sevoflurane that was blocked by MnTBAP but not by the putative K_{ATP} antagonist 5-HD.

D. Biphasic effect of K_{Ca} channels on ROS generation

We have postulated that mitochondrial K_{Ca} channels can modulate ROS production up or down by altering ΔpH independent of $\Delta\Psi_m$ (158, 159). We proposed that opening K_{Ca} channels with NS1619 produces a small H^+ leak (Fig. 28) (159). Others have proposed that K^+ cycling can account for no more than a small H^+ leak (49, 50). The increase in K^+ influx may be rapidly matched by K^+ efflux and H^+ influx *via* KHE driven by the pH gradient. As K^+ enters the matrix electrophoretically *via* K^+ channels (*e.g.*, during ischemia due to Ca^{2+} loading and low ATP during ischemia) K^+ may be exchanged for the energetically more favorable entry of H^+ (leak) because of the large ΔpH . If the inward H^+ leak is small, a small increase in proton pumping by complexes I, III, and IV enhances the respiratory rate without decreasing $\Delta\Psi_m$, while promoting ROS release (Fig. 29). K^+ flux could be a mechanism by which increased matrix Ca^{2+} modulates

respiration. When the H^+ leak is large, $\Delta\Psi_m$ (and $O_2^{\bullet-}$ generation) would decrease, as discussed with other mechanisms of the H^+ leak (section VI).

If K^+ flux mediates an H^+ leak through KHE, then blocking KHE (quinine) should increase matrix K^+ but not H^+ levels. In preliminary experiments in isolated cardiac mitochondria, we observed that valinomycin, the putative K_{Ca} channel opener NS1619, and buffer Ca^{2+} increased matrix K^+ only in the presence of KHE blockade and that matrix pH decreased only in the absence of KHE (3, 4). A caveat to our work is that NS1619 has been reported (74) also to act as a protonophore, in which case, a small direct H^+ leak, rather than K^+ flux and KHE, might lead to the increase in H_2O_2 if $\Delta\Psi_m$ remains unchanged. Thus, although a large proton leak would be expected to act as a brake on further ROS generation, a small proton leak that stimulates respiration without reducing $\Delta\Psi_m$ may actually slightly increase ROS to modulate cell-signaling pathways. Moreover, in a recent study in which K^+ flux across the matrix was assessed indirectly by swelling and respiratory changes induced by valinomycin (K^+ ionophore) and nigericin (KHE activator), the putative K^+ channel openers NS1619 and diazoxide could not be shown to enhance K^+ flux (30).

E. K_{ATP} channel opening and ROS

A putative mitochondrial K_{ATP} channel opener was also reported to increase ROS production (Fig. 30), but by an alternative mechanism (9). In the presence of ATP, diazoxide increased ROS in isolated mitochondria, and the effect was inhibited by 5-hydroxydecanoate (5-HD); it was hypothesized that matrix K^+ influx causes matrix alkalinization, which retards electron transfer at complex I to cause electron leak and ROS formation (9).

The mitochondrial effects of drugs can be different, depending on the substrates used, their concentrations, and the bioenergetics state. For example, in isolated cardiac mitochondria, we found that two putative K_{ATP} channel openers (diazoxide and pinacidil) differentially attenuated mitochondrial respiration and that K_{ATP} channel antagonists (5-HD and glibenclamide) had no effect on this

(270). But when ATP synthase was inhibited by oligomycin, both K_{ATP} channel openers accelerated respiration, which was abolished by the K_{ATP} channel inhibitors. Many drugs also have biphasic effects, largely because they have concentration-dependent effects on mitochondrial energetics. For example, the various putative types of mitochondrial K^+ channel openers at low concentrations accelerate respiration and ROS generation without altering $\Delta\Psi_m$ or redox state (9, 159), whereas larger concentrations accelerate respiration even more, depolarize $\Delta\Psi_m$, and decrease the redox state and ROS generation (105, 130, 159). Moreover, these openers may have primary (74, 162) or secondary (159) effects to induce a proton leak into the matrix and may not actually open mitochondrial K^+ channels.

Thus, drugs that act on mitochondria can have biphasic as well as nonspecific effects, which complicate our understanding of mitochondrial function. As noted elsewhere, all these findings in isolated mitochondria are highly condition dependent and may not represent what occurs in intact tissue preparations. Further studies are necessary to determine the mechanism and extent to which specific mitochondrial K^+ channels do or do not modulate ROS at physiologic levels. That these channels are sensitive to either low ATP levels or high Ca^{2+} levels suggests that they could have important roles in mitochondrial regulation. Although many of the drugs used to assess ion channels in cell membranes may have specificity for a particular channel, the drugs used to assess mitochondrial channel function (*e.g.*, diazoxide or NS1619) do not appear to be specific for these channels but nevertheless exert protective function by an uncoupling mechanism and or by stimulation of ROS-dependent pathways.

F. Direct Ca^{2+} -induced ROS unlikely

Does Ca^{2+} directly modulate ROS? Ischemia and reperfusion result in increases in both Ca^{2+} and ROS, but it is unlikely that Ca^{2+} itself modulates ROS physiologically for the following reasons: (a) in pathologic situations, excess ROS results in Ca^{2+} loading, but not the other way around (72); (b) excess Ca^{2+} loading will itself cause MPT pore opening and dissipation of the $\Delta\Psi_m$ (72), but ROS-induced MPT pore opening does not require Ca^{2+} loading (186); (c) a Ca^{2+} -induced increase in oxidative phosphorylation (and decreased $\Delta\Psi_m$) tends to

decrease ROS, not to increase ROS (59, 72, 243, 296); (d) excess Ca^{2+} increases ROS only when mitochondrial inhibitors are used; otherwise, ROS decreases (59, 65); (e) blocking mitochondrial Ca^{2+} flux does not interfere with bursts of ROS produced by mitochondria during a local laser flash (11); and (f) $\text{O}_2^{\bullet-}$ -induced mitochondrial swelling is Ca^{2+} independent, but Ca^{2+} -induced swelling is ROS dependent (127, 194). However, the possibility that Ca^{2+} -induced MPT pore opening, leading to loss of cytochrome *c*, differentially alters the matrix and IMS levels of ROS is discussed in section V.

G. Rate of oxidative phosphorylation and ROS generation

As discussed in section III, it is well known from O_2 -consumption experiments in mitochondria that the state 3 to state 4 transition is usually accompanied by enhanced ROS production. Uncoupling (increased respiration without increased phosphorylation) typically leads to reduced ROS production, so it is possible that a change in the rate of oxidative phosphorylation modulates the rate of $\text{O}_2^{\bullet-}$ generation. Moderate increases in $m[\text{Ca}^{2+}]$ induced by cell-receptor stimulation have long been thought to stimulate TCA-cycle substrate dehydrogenases and ATP synthase (108, 227, 228). However, it appears that this Ca^{2+} -induced stimulation is a slow process, because the dynamic, rapid stimulation of oxidative phosphorylation is not inhibited by partially blocking mitochondrial Ca^{2+} entry (148). Oxidative phosphorylation is activated with a time constant of seconds for the creatinine kinase system with an increase in ATP hydrolysis (313) that is too fast for Ca^{2+} to enter the matrix (52, 232). The prevailing view has been that oxidative phosphorylation is not governed by feedback control (17, 18, 51, 52, 180, 226). Computer simulations of increased cardiac work demands indicate that neither direct activation of ATP use alone nor a direct activation of both ATP use and substrate dehydrogenation, including Ca^{2+} -dependent TCA-cycle dehydrogenases, can account for the constancy of [ATP], [PCr] [Pi], and [NADH] during an increase in O_2 consumption in hearts in vivo (192, 193). Rather it was proposed that a so-called "each-step-activation" (or parallel-activation) mechanism is the explanation, in which all oxidative phosphorylation complexes are directly activated by some cytosolic factor related to muscle

contraction in parallel with activation of ATP use and Ca^{2+} -dependent TCA-cycle dehydrogenases. This is a broad concept difficult to disprove. Others have proposed that oxidative phosphorylation in the heart is not likely regulated by quickly diffusing ADP and P_i in a simple feedback-control system (314). But another computer simulation (26), which incorporated each respiratory complex, substrate transporters including ANT, and cation fluxes, obtained reasonable fits to published data if P_i -dependent activation of dehydrogenase activity and the electron-transport system (especially complex III) were incorporated. Further development of this model (329) predicted that NAD is a more important regulator than ADP of the TCA-cycle dehydrogenases, and that a decrease in cytosolic pH decreases $\Delta\Psi_m$ and the ability to synthesize ATP.

Phosphorylation of complex IV at high matrix ATP/ADP ratios is known to decrease the H^+/e^- stoichiometry (H^+ "slip") of the complex inducing an intrinsic form of uncoupling in which the efficiency of proton pumping is reduced (see also section VII). Respiratory control is generally defined as the increase in respiration in the presence of ADP and its decline once ADP is phosphorylated. A possible mechanism for control of ROS release by oxidative phosphorylation may arise from a "second mechanism of respiratory control," in which a high matrix ATP/ADP ratio is thought to allosterically inhibit complex IV (219). This inhibition of cytochrome c oxidase is switched on by cAMP-dependent phosphorylation and switched off by Ca^{2+} -activated dephosphorylation (179). cAMP-dependent phosphorylation of cytochrome c oxidase may optimize the efficiency of oxidative phosphorylation by maintaining a low $\Delta\Psi_m$ via the second mechanism of respiratory control. The effect of NO^* to compete with O_2 for binding at complex IV is discussed in section IV. Extrinsic uncoupling (H^+ "leak") of oxidative phosphorylation (e.g., UCPs, HNE) is described in section VII.

IX. Role of ROS in Triggering or Effecting Cardioprotection

A. Pathways and mechanisms

Preconditioning is defined by the removal of the stimulus (brief ischemia or drug) some time before the onset of ischemia. Thus, the

stimulus does not directly induce the cardioprotection but rather some downstream factors do. Much circumstantial evidence suggests that mitochondria-derived ROS play an important role to initiate ischemic preconditioning (IPC) (Fig. 19) and pharmacologic preconditioning (PPC) (90, 100, 101, 217, 271, 306), which is effected by protein kinase pathways (223, 224, 247). Earlier studies examined the role of K_{ATP} channel openers and inhibitors to elicit and to block PPC. A common denominator of these studies was the finding that PPC, induced by the putative mitochondrial K_{ATP} channel opener diazoxide, could be blocked by ROS scavengers such as *N*-acetylcysteine (124) or *N*-mercapto-propionyl-glycine (254). A mild ROS stress, *per se*, triggered cardioprotection by activating protein kinases, but ROS also were reported to activate sarcolemmal K_{ATP} channels by modulating ATP binding at this channel, as this effect was blocked either by glibenclamide or by ROS scavengers (304, 305). Conversely, IPC requires ROS independent of K_{ATP} channel activity (120). Both K_{ATP} channel opening and H_2O_2 inhibit MPT pore opening (94). These and other studies suggested that a feedback loop may exist between K_{ATP} channels and ROS to produce cardioprotection (205, 237, 272, 298, 299), but much of this remains unresolved, in part because many of the drugs used as probes have other effects on cell or mitochondrial function (103, 154–156, 259). Kukreja (198) addressed the controversy in this area.

Mitochondrial Ca^{2+} -dependent K^+ channel (K_{Ca}) as well as K_{ATP} channel openers may play major roles not only in modulating mitochondrial bioenergetics but also in cardioprotection against ischemia/reperfusion injury. Most is reported about the putative K_{ATP} channel (1, 130, 131, 178, 195, 236). Mitochondrial K_{Ca} openers, like K_{ATP} channel openers, appear to mediate their effects through ROS-dependent mechanisms, as ROS scavengers, such as MnTBAP, block the protection (Figs. 18 and 19) (181, 183, 298). Figure 31 shows that paxilline (PX, an inhibitor of K_{Ca} channels) and MnTBAP (TB, an $O_2^{\bullet-}$ dismutator) blocked the ROS (DHE) and redox (NADH) reducing effect of NS119 (putative K_{Ca} channel opener) during ischemia and reperfusion of isolated hearts. Diverse cardiac-preconditioning drugs given before ischemia and reperfusion in isolated hearts result in improved function along with improved tissue redox state (NADH and FAD), reduced cytosolic and mitochondrial Ca^{2+} loading, and reduced

production of $O_2^{\bullet-}$ and $ONOO^-$ during ischemia and reperfusion (76, 181, 248, 298). If the observed changes in isolated mitochondria by mild K^+ flux that promotes the increase in $O_2^{\bullet-}$ (observed *via* dismutation to H_2O_2) also occur *in vivo*, then modulation of mitochondrial bioenergetics by K^+ flux might ultimately be a key initiator of mitochondrial and cell protection.

B. Inhibiting complex I and cardioprotection

Another approach to protect cells undergoing ischemia is to inhibit complex I during ischemia (81). Rotenone or amobarbital (a reversible inhibitor of complex I) given just before the onset of cardiac ischemia resulted in improved oxidative phosphorylation and retention of cytochrome *c* in mitochondria isolated during ischemia or on reperfusion (82, 85). We found subsequently that amobarbital, *per se*, when given for 1 min before ischemia, arrested hearts, increased $O_2^{\bullet-}$ emission (and NADH, with no change FAD), and reduced mitochondrial $[Ca^{2+}]$ (Fig. 32) (5); this led to reduced $O_2^{\bullet-}$ generation and mitochondrial $[Ca^{2+}]$ during ischemia and reperfusion. These *ex vivo* results suggested that amobarbital blocks electron transfer upstream of the rotenone binding site but distal to the NAD⁺ binding site. During reperfusion after ischemia, we observed a more reduced NADH redox state, decreased $O_2^{\bullet-}$ generation, and reduced mitochondrial $[Ca^{2+}]$ in this intact heart model (5). These mitochondria-protective effects were accompanied by improved cardiac function and smaller infarct size.

X. Regulation of Cellular Processes by Mitochondria-Derived ROS

Intracellular signaling pathways (*e.g.*, Ca^{2+} , cAMP, protein phosphorylation–dephosphorylation cascades) are essential for modulating cell metabolism and function. Many of these pathways are linked to extracellular receptor ligands at the plasma membrane, but many are derived from within the cell (*e.g.*, the feedback link between the cell's metabolic rate and mitochondrial respiratory activity). Accumulating evidence indicates that ROS are not always deleterious but are essential participants in cell signaling (113, 126, 163, 303). Whether ROS are “bad” or “good” could simply be a matter of quantity or rate of production, or it may also depend on the specific species,

the site of generation, and the site of ROS release. The important and well-examined role of non-mitochondriaderived ROS ($O_2^{\bullet-}$ and NO^{\bullet}) in vascular sensing and control (328) is not addressed here. The "pathologic" roles of ROS and Ca^{2+} loading during cellular stress [e.g., ischemia, hypoxia that lead to induction of cell necrosis and apoptosis (68, 207, 323, 330)] were addressed in section III.

A. Cell signaling by oxidative modifications and redox systems

ROS-induced cell signaling involves two general mechanisms: alterations in the intracellular redox state (e.g., GSH, TRXSH₂, and other redox systems) (Fig. 21) and oxidative modification of proteins (92, 303). ROS appear to regulate a large number of signaling pathways that modulate cell function, but the actual molecules targeted by the ROS are unclear in most cases. Evidence for a physiological role of ROS emission are based in part on the effects of antioxidants and inhibitors of ROS generation to prevent growth factor and cytokine-activated signals, or some other physiological effect, and the effects of exogenously applied oxidants to activate these responses.

Synchronized oscillations in $\Delta\Psi_m$, the redox states of NADH, GSH/GSSG and other redox pairs, and ROS can occur across isolated cardiomyocytes (11) and were postulated to result from the balance between $O_2^{\bullet-}$ efflux through IMM anion channels (IMAC) and the intracellular ROS scavenging capacity. This was based on a computational model (93) of mitochondrial energetics and Ca^{2+} handling that reproduced the observed oscillations, which could be modulated by ROS scavengers or by the rate of oxidative phosphorylation. Oxidation of thiol groups appears to govern the sequential opening of IMAC (before MPT pore opening occurs), based on the GSH/GSSG redox status (10). Such oscillations may play a role in physiologic timekeeping or redox signaling across the cell or both.

B. Examples of signaling by ROS

The role of ROS in initiating preconditioning protection, particularly well known in the heart, is a vivid example of how ROS

modulate cell signaling by mitochondrially generated ROS. To be a modulator of physiological function, the oxidizing effect of ROS should be transient and reversible, generally by other reducing agents. Broad examples of ROS (typically H₂O₂)-induced signaling (266) are inhibition of tyrosine phosphatase (278, 315) leading to cell proliferation; translocation and activation of serine/threonine kinases, such as protein kinase C (247, 301) and tyrosine hydroxylase mRNA, the rate-limiting enzyme in catecholamine biosynthesis (196); activation of the MAPK family of protein kinases (including MAPKs ERK, JNK, p38) that mediate mitogen and stress-activated signals; NF- κ B, a transcription factor that regulates gene expression involving immune and inflammation responses; and AP-1, a transcription complex (303).

One example of a regulatory feedback loop between ROS signaling and enzyme modification is the following: pyruvate was shown to activate JNK1 indirectly *via* pyruvate-induced mitochondrial H₂O₂ release (242); in turn, JNK1 inhibited the activity of the metabolic enzymes glycogen synthase kinase 3 β , allowing increased activity of glycogen synthase so that glucose was stored as glycogen rather than undergoing glycolysis. Thus substrate metabolism can be tied directly to mitochondrial ROS. Ion-channel function is also subject to modification by thiol reducing and oxidizing agents (73, 163, 164).

C. Importance of cysteine thiols in ROS-induced signaling

How ROS modify the structure and function of these and other signaling proteins is not well understood, but several mechanisms are described (163, 303), particularly those involving the key thiol groups in regulatory proteins (20). One is the reversible oxidation of the sulfhydryl group (–SH) in the cysteine residue to form SOH, SO₂H, or SO₃H derivatives that alter the activity of an enzyme if the cysteine is located in a catalytic domain or DNA-binding site. For example, H₂O₂-induced oxidation of a cysteine residue located in its catalytic site precisely and rapidly inhibits tyrosine phosphatase (278, 315). The modification of –SH to –SO₂H prevents the enzyme from further oxidation and promotes reversibility to its active form (except for SO₃H) by thiols (278, 315).

Another mechanism for posttranslational protein modification by ROS (Fig. 7) is a conformational change in the structure of protein kinases by formation of intramolecular disulfide bridges in cysteine linkages. Another is protein dimerization by intermolecular disulfide linkages of monomers to form an active protein, or dissociation of an inactive protein complex linked by disulfide linkages into an active protein. Several proteins can also become cross-linked because of active dityrosine formation from two tyrosine molecules by H₂O₂ peroxidase-dependent reactions. Mixed-function oxidases can facilitate metal-catalyzed oxidation by O₂^{•-} of proteins with 4Fe-4S tetranuclear cores to mark them for ubiquitination and so alter their stability (303). To qualify as cell-signaling pathways, these oxidation reactions should be reversible by using the cell's redox systems (*e.g.*, GSH and TRXSH₂), as discussed previously.

D. ROS oxidation reactions

Precursor ROS do not always oxidize proteins directly but rather through an oxidized and reactive phospholipid intermediary (Fig. 23). Oxidized lipids can activate cell signaling pathways by non-covalent bonding to a receptor, by covalent binding with direct modification of the protein, and by activating pathways that induce ROS formation from other sources (334). The electrophilic lipid peroxidation product 4-HNE (section VI) causes ROS emission that activates MAPK pathways (311), and 4-HNE selectively inactivates thiol containing proteins, such as α -ketoglutarate dehydrogenase and pyruvate dehydrogenase, and thus inhibits NADH-dependent respiration (complex I) (168).

E. O₂ sensors

A physiologic response to low O₂ requires an O₂ sensor coupled to a signal-transduction system (80). For example, ATP synthesis is tightly proportional to O₂ consumption in the presence of adequate O₂, so the ability of the cell to sense a critically low level of O₂ would appear to be fundamental to restoring O₂ levels for ATP synthesis (45). But the molecular identity or mechanism of an O₂ sensor has not been forthcoming. Several O₂-sensor mechanisms have been proposed and reviewed (80): O₂-sensitive heme proteins; O₂-sensitive ion channels;

O₂-sensitive NADPH oxidase; O₂-sensitive complex IV; and O₂-sensitive ROS generation. Many of the proposed O₂ sensors do not appear to have the sensitivity to act directly as O₂ sensors, but they could all be linked to hypoxia-induced changes in redox state or ROS generation. For example, the capacity of complex IV to produce H₂O from O₂, electrons, and protons is not impaired at even very low pO₂ values, but enzyme activity (V_{max}) is reduced so that reduced electron transfer and a more reduced redox state ensue (80).

F. Hypoxia-inducible factors

A principal regulator of the response to hypoxia is the hypoxia-inducible factor (HIF) family of transcription factors (31, 61, 115, 165, 177, 185, 221, 282–286, 316, 327). Although constitutively expressed, the HIF-1 α subunit has a very short half-life in normoxic conditions because of its rapid hydroxylation by prolyl-4 hydroxylases (PH1–3) (12, 36). During hypoxia, the HIF-1 α subunit becomes uninhibited by PHs, so that HIF-1 α accumulates and transfers to the nucleus to initiate HIF-1 α -mediated transcription of more than 70 genes involved in protein stability, such as heat-shock proteins (HSPs) (40). Therefore, low O₂ would appear to control activation of HIF-1 α by inhibiting PH activity. The mitochondrion would seem to be a natural sensor for O₂ because complex IV is where O₂ binding and O₂ consumption occur. However, blocking complex III with antimycin A and cyanide to block complex IV did not inhibit the HIF-1 α in isolated cardiomyocytes in response to hypoxia (79). Moreover, inhibition of PH did not occur until O₂ levels were below 5%, with maximal activation at 0.5% O₂ (177). Rather than O₂ being the actual sensor, it was proposed that the actual sensor is the redox changes upstream from complex IV (146).

The signaling consequences of hypoxia are probably modified by NO[•]. Nitric oxide, and other inhibitors of mitochondrial respiration, can prevent stabilization of HIF-1 α during hypoxia as a result of an increase in PH-dependent degradation of HIF-1 α (147). During inhibition of mitochondrial respiration by hypoxia, O₂ was found to redistribute toward nonrespiratory O₂-dependent targets such as PHs, so that they no longer registered hypoxia (147). It was concluded that NO[•] acts as an endogenous regulator of intracellular O₂ availability;

inhibition of mitochondrial O₂ consumption may create a paradox of increased O₂ availability for prolyl hydroxylation of HIF-1 α , so that the cell may fail to register hypoxia. In a related study (222), lower concentrations of NO[•] (<400 nM) caused a rapid decrease in HIF-1 α stabilized by exposing cells to 3% O₂. This effect of NO[•] was dependent on inhibition of mitochondrial respiration, because the NO[•] effect was mimicked by other inhibitors of mitochondrial respiration, including those not acting at complex IV. It was suggested that although stabilization of HIF-1 α by high level of NO[•] may have pathologic consequence, the inhibitory effect of low levels of NO[•] may be physiologically relevant.

G. ROS as O₂ sensors

It has been suggested that O₂ sensing by the cell is actually carried out by mitochondrial ROS (31, 61, 80, 146, 221), including NO[•] (57). One proposal is that the increase in mitochondrial redox state secondary to the reduced V_{max} of complex IV during hypoxia creates a more favorable condition for O₂^{•-} generation and downstream ROS production (Fig. 33) (80). Thus, the common denominator for O₂ sensing by ROS would be the heightened redox state and $\Delta\Psi_m$ or both. However, the mechanism for the reduction in V_{max} by low O₂ levels is not known.

Support for a role of ROS in HIF-1 α stabilization derives from studies showing that the absence of cytochrome *c* or blocked Rieske Fe-S proteins under hypoxic conditions blocks HIF-1 α stabilization (61, 221). How H₂O₂ inhibits PH activity is not yet known, but likely involves one of the ROS- induced protein modifications discussed earlier. When iron chelators were given to block Fe²⁺ from reacting on PH, or HIF-1 α hydroxylation was prevented by 1-dimethylallyl glycine (DMOG) to compete at PH, HIF-1 α accumulated and induced gene expression (173). These mechanisms depend on the observed increase in mitochondrial ROS in cells when O₂ levels decrease during hypoxia and ischemia. However, this must be reconciled by the finding in isolated mitochondria that hypoxia does not itself increase ROS (Fig. 20) (161). Thus, it has been proposed that the hypoxic signal is a decrease in ROS, not an increase (13, 184, 233, 326). Studies in intact cells, tissue and isolated hearts indicate that ROS emission increases

during hypoxia and ischemia, as discussed earlier (section III), so the controversy on the actual hypoxia-sensing mechanism continues.

H. Peroxide-induced TCA shunts

Peroxides produced by mitochondria can create nonenzymatic shunts in the TCA cycle (56, 121). Succinate dehydrogenase (complex II) is very resistant to oxidation by H₂O₂ or *tert*-butyl hydroperoxide (*tert*-BuOOH) (250), but α -ketoglutarate dehydrogenase activity is markedly decreased (168, 250) because of its susceptibility for modification by peroxides of its thiol groups (167, 249). Although this decreases the enzymatic conversion of α -ketoglutarate to succinyl Co-A and succinate by decarboxylation and blocks production of reducing equivalents (NAD⁺ to NADH) at this step, these oxidants nonenzymatically (chemically) decarboxylate α -ketoglutarate to succinate and thus reduce the level of peroxides (Fig. 34) (121). This bypass depends on a supply of α -ketoglutarate by transamination because its precursor, aconitate, is also inactivated by peroxides (62, 249). This TCA bypass increases the contribution of succinate to the total energy supply (FADH₂ dependent) while decreasing the NADH-dependent energy supply (168). Because succinate can contribute to reverse electron transfer and generation at complex I under certain conditions, control of succinate levels during acute cell stress may be beneficial. Another peroxide bypass, the electron-leak pathway mediated by cytochrome *c* (332, 333), was discussed in section VII.

Hypoxia, increased succinate, and decreased α -ketoglutarate can each lead to inhibition of PH (208, 281), which permits translocation of HIF- α to the nucleus to support HIF- α -dependent transcription of the multitude of genes responsible for O₂ transport, vascularization, and anaerobic energy production (208). Addition of succinate improved oxidative phosphorylation after ischemia/reperfusion injury (69), so the role played by succinate is not well understood. These studies again point to H₂O₂ (and other peroxides), rather than O₂^{•-} *per se*, as the transduction factor in physiologic regulation by ROS (61). Modulation of a key TCA intermediate, in this case succinate, by ROS is a prime example for demonstrating how mitochondria and cells respond to oxidative stress by altering gene expression. If ischemia or hypoxia induces reverse electron transfer by a TCA shunt to the FAD-

linked substrate succinate because of inhibition of the NADH-linked substrates, the resulting increase in $O_2^{\bullet-}$ generation at complex I may signal measures to alter mitochondrial function. It was noted earlier that inhibiting complex I with amobarbital improved cardiac function after ischemia and reperfusion and improved mitochondrial function (5, 85). Thus, it is possible that reverse electron transfer may be, at least in part, responsible for some of the increase in ROS during ischemia. As discussed in section III, NADH-linked substrates do not appreciably block succinate-induced H_2O_2 emission via reverse electron transfer (335).

XI. Summary

A. Difficulties in understanding the role of ROS

Although H_2O_2 , and in some situations, $O_2^{\bullet-}$ (21), are found to trigger a multitude of signaling pathways (most unknown) *via* their reactants such as peroxides, the precise mechanisms by which mitochondrial ROS initiate the signal-transduction pathways are mostly unknown, despite the TCA succinate bypass example given earlier. One difficulty in a better understanding of ROS modulation of cell signaling is the short half-life and reactive state of many ROS. The source or compartmentalization of the ROS is difficult to discern in most situations. The original oxidation product may itself be oxidized to a product that is the active signaling molecule. A surge in ROS or changes in redox capacity may have local or broad effects on many regulatory proteins simultaneously, so determining specificity is difficult. The ROS can originate from extracellular, cytosolic, or a nonmitochondrial organelle, or from a combination of extra- and intramitochondrial compartments. Moreover, redox regulation of ROS occurs at multiple levels. All of these complicating factors make it quite difficult to sort out the exact signaling mechanisms of ROS. It would appear that Nature has developed a highly sophisticated system to regulate specifically the generation and scavenging of ROS and to modulate the downstream effects of physiologically induced ROS emission on mitochondrial and cell activity.

B. Future directions

From this review, it is clear that much has been learned about mitochondrial sources of ROS, the mechanisms of ROS generation and scavenging, and the pathologic effects of "bad" ROS on cell processes. However, knowledge of the source, amount, generation site, and specific "good" reactive species that are involved in cellular and organelle protection and physiologic modulation of cellular activity, even in one cell type (*e.g.*, the cardiac myocyte), remains in its infancy. We hope that future studies will refine and detail our specific understanding of cell-signaling pathways mediated by mitochondrial ROS by using more physiologic approaches in normal cell settings. From these studies, it is hoped that novel therapeutic targets and drugs can be discovered by which to treat mitochondrial and cellular stresses, or at least to assist the organism's intrinsic protective mechanisms.

Footnotes

Reviewing Editors: Hossein Adrehali, Juan Bolaños, Enrique Cadenas, Sergey Dikalov and Rodrigue Rossignol

Acknowledgments

We thank Mohammed Aldakkak, M.D., and Johan Haumann, M.D., for their careful review and critique of this manuscript. This work was supported in part from the National Institutes of Health (HL089514 to D.F.S. and HL073246 to A.K.S.C.), VA Research Merit Award 8204-05P (to D.F.S.), and a Grant-in Aid from the American Heart Association (0855940G to D.F.S.)

Abbreviations

2-OH-E+, 2-hydroxyethidium; 5-HD, 5-hydroxydecanoic acid; $\Delta\mu\text{H}^+$, proton motive force, transmembrane electrochemical H^+ potential difference; $\Delta\Psi_{\text{m}}$, mitochondrial transmembrane potential; $\Delta\text{pH}_{\text{m}}$, mitochondrial pH gradient potential; ANT, adenine nucleotide translocase; CAT, carboxyatractyloside; CCCP, carbonyl-cyanide-*m*-chlorophenylhydrazenone; DCF, 2',7'-dichlorofluorescein; DHE, dihydroethidium; DMOG, 1-dimethyloxallyl glycine; ETS, electron-transport system; FADH₂, flavin adenine dinucleotide (reduced); GSH, glutathione (reduced); H₂O₂, hydrogen peroxide; HIF,

hypoxia inducible factor; HNE, 4-hydroxy-*trans*-2-nonenal; IMAC, inner membrane anion channel; IMM, inner mitochondrial membrane; IMS, intermembrane space; IPC, ischemic preconditioning; K_{ATP} , ATP-sensitive K^+ channel; K_{Ca} , Ca^{2+} -sensitive K^+ channel; KHE, K^+/H^+ exchange; L-NAME, N^G -nitro-L-arginine methyl ester; MAPK, ERK, JNK, p38, family of protein kinases; MnTBAP, Mn(II)tetrakis(4-benzoate) porphyrin chloride; MPG, *N*-(2-mercaptopropionyl)glycine; MPT, mitochondrial permeability transition; NADH, nicotinamide adenine dinucleotide (reduced); NHE, Na^+/H^+ exchange; NO^* , nitric oxide radical; $O_2^{\bullet-}$, superoxide anion radical; OMM, outer mitochondrial membrane; $ONOO^-$, peroxynitrite; PH, prolyl-4-hydroxylase; PHP, phospholipid hydroperoxide; PPAR- γ , peroxisome proliferator activated receptor gamma; PPC, pharmacologic preconditioning; Prx3, Prx5, peroxiredoxins 3 and 5; Pr-SSG, glutathione-protein mixed disulfides (oxidized); Q, coenzyme Q_{10} , ubiquinone, quinone; ROS, reactive oxygen species; SOD, superoxide dismutase; TCA, tricarboxylic acid; TRXSH₂, thioredoxin (reduced); UCP, uncoupling proteins.

Disclosure Statement

No competing financial interests exist.

References

1. Akao M, O'Rourke B, Teshima Y, Seharaseyon J, and Marban E. Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. *Circ Res* 92: 186–194, 2003.
2. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. *Molecular biology of the cell*. New York: Garland Publishing, 1994.
3. Aldakkak M, Camara AKS, Beard DA, Dash RK, Huang M, and Stowe DF. NS1619 increases potassium influx in the isolated intact mitochondrion in a dose-dependent manner [Abstract]. *Biophys J* pos-441, 2007.
4. Aldakkak M, Camara AKS, Patel R, Haumann J, Rhodes SS, and Stowe DF. Inactivation of cardiac mitochondrial K/H exchange by quinone exposes matrix acidification and K^+ influx by putative Ca^{2+} -dependent K^+ channels [Abstract]. *J Biophysics* 436-pos, 2008.
5. Aldakkak M, Stowe DF, Chen Q, Lesnefsky EJ, and Camara AK. Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca^{2+} overload and ROS release. *Cardiovasc Res* 77: 406–415, 2008.
6. Ambrosio G, Zweier JL, Duilio C, Kuppusamy P, Santoro G, Elia PP, Tritto I, Cirillo P, Condorelli M, Chiariello M, and Flaherty JT. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free

- radicals in intact rabbit hearts subjected to ischemia and reflow. *J Biol Chem* 268: 18532–18541, 1993.
7. An J, Camara AK, Riess ML, Rhodes SS, Varadarajan SG, and Stowe DF. Improved mitochondrial bioenergetics by anesthetic preconditioning during and after 2 hours of 278C ischemia in isolated hearts. *J Cardiovasc Pharmacol* 46: 280–287, 2005.
 8. Andreyev AY, Kushnareva YE, and Starkov AA. Mitochondrial metabolism of reactive oxygen species. *Biochemistry (Mosc)* 70: 200–214 [review], 2005.
 9. Andrukhiv A, Costa AD, West IC, and Garlid KD. Opening mitoK_{ATP} increases superoxide generation from complex I of the electron transport chain. *Am J Physiol Heart Circ Physiol* 291: H2067–H2074, 2006.
 10. Aon MA, Cortassa S, Maack C, and O'Rourke B. Sequential opening of mitochondrial ion channels as a function of glutathione redox thiol status. *J Biol Chem* 282: 21889–21900, 2007.
 11. Aon MA, Cortassa S, Marban E, and O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. *J Biol Chem* 278: 44735–44744, 2003.
 12. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, and Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. *J Biol Chem* 279: 38458–38465, 2004.
 13. Archer SL, Huang J, Henry T, Peterson D, and Weir EK. A redox-based O₂ sensor in rat pulmonary vasculature. *Circ Res* 73: 1100–1112, 1993.
 14. Azzu V, Parker N, and Brand MD. High membrane potential promotes alkenal-induced mitochondrial uncoupling and influences adenine nucleotide translocase conformation. *Biochem J* 413: 323–332, 2008.
 15. Baines CP, Goto M, and Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. *J Mol Cell Cardiol* 29: 207–216, 1997.
 16. Baker JE, Felix CC, Olinger GN, and Kalyanaraman B. Myocardial ischemia and reperfusion: direct evidence for free radical generation by electron spin resonance spectroscopy. *Proc Natl Acad Sci U S A* 85: 2786–2789, 1988.
 17. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. *J Mol Cell Cardiol* 34: 1259–1271, 2002.
 18. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. *Am J Physiol* 258: C377–C389, 1990.
 19. Ball AM and Sole MJ. Oxidative stress and the pathogenesis of heart failure. *Cardiol Clin* 16: 665–675, viii–ix, 1998.

20. Barford D. The role of cysteine residues as redox-sensitive regulatory switches. *Curr Opin Struct Biol* 14: 679–686, 2004.
21. Barrett WC, DeGnore JP, Keng YF, Zhang ZY, Yim MB, and Chock PB. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of proteintyrosine phosphatase 1B. *J Biol Chem* 274: 34543–34546, 1999.
22. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, and Leverve XM. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. *J Bioenerg Biomembr* 38: 33–42, 2006.
23. Bates TE, Loesch A, Burnstock G, and Clark JB. Immunocytochemical evidence for a mitochondrially located nitric oxide synthase in brain and liver. *Biochem Biophys Res Commun* 213: 896–900, 1995.
24. Bates TE, Loesch A, Burnstock G, and Clark JB. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? *Biochem Biophys Res Commun* 218: 40–44, 1996.
25. Baudry N, Laemmel E, and Vicaut E. In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondria. *Am J Physiol Heart Circ Physiol* 294: H821–H828, 2008.
26. Beard DA. A biophysical model of the mitochondrial respiratory system and oxidative phosphorylation. *PLoS Comput Biol* 1: e36, 2005.
27. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. *Cardiovasc Res* 61:461–470 [review], 2004.
28. Becker LB, Vanden Hoek TL, Shao ZH, Li CQ, and Schumacker PT. Generation of superoxide in cardiomyocytes during ischemia before reperfusion. *Am J Physiol Heart Circ Physiol* 277: H2240–H2246, 1999.
29. Beckman JS, Chen J, Ischiropoulos H, and Crow JP. Oxidative chemistry of peroxynitrite. *Methods Enzymol* 233: 229–240, 1994.
30. Bednarczyk P, Barker GD, and Halestrap AP. Determination of the rate of K⁺ movement through potassium channels in isolated rat heart and liver mitochondria. *Biochim Biophys Acta* 1777: 540–548, 2008.
31. Bell EL, Emerling BM, and Chandel NS. Mitochondrial regulation of oxygen sensing. *Mitochondrion* 5: 322–332 [review], 2005.
32. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, and Chandel NS. The Q_o site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. *J Cell Biol* 177: 1029–1036, 2007.
33. Benov L, Szejnberg L, and Fridovich I. Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical. *Free Radic Biol Med* 25: 826–831, 1998.
34. Bernardi P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. *Physiol Rev* 79: 1127–1155, 1999.

35. Bernardi P, Colonna R, Costantini P, Eriksson O, Fontaine E, Ichas F, Massari S, Nicolli A, Petronilli V, and Scorrano L. The mitochondrial permeability transition. *Biofactors* 8: 273–281, 1998.
36. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 α in normoxia. *EMBO J* 22: 4082–4090, 2003.
37. Bienert GP, Moller AL, Kristiansen KA, Schulz A, Moller IM, Schjoerring JK, and Jahn TP. Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes. *J Biol Chem* 282: 1183–1192, 2007.
38. Bienert GP, Schjoerring JK, and Jahn TP. Membrane transport of hydrogen peroxide. *Biochim Biophys Acta* 1758: 994–1003, 2006.
39. Bolanos JP, Garcia-Nogales P, and Almeida A. Provoking neuroprotection by peroxynitrite. *Curr Pharm Des* 10: 867–877, 2004.
40. Borger DR and Essig DA. Induction of HSP 32 gene in hypoxic cardiomyocytes is attenuated by treatment with Nacetyl-L-cysteine. *Am J Physiol Heart and Circ Physiol* 274: H965–H973, 1998.
41. Boss O, Samec S, Paoloni-Giacobino A, Rossier C, Dulloo A, Seydoux J, Muzzin P, and Giacobino JP. Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. *FEBS Lett* 408: 39–42, 1997.
42. Boveris A and Cadenas E. Mitochondrial production of superoxide anions and its relationship to the antimycin insensitive respiration. *FEBS Lett* 54: 311–314, 1975.
43. Boveris A, Cadenas E, and Stoppani AO. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. *Biochem J* 156: 435–444, 1976.
44. Boveris A and Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 134: 707–716, 1973.
45. Boveris A, Costa LE, Poderoso JJ, Carreras MC, and Cadenas E. Regulation of mitochondrial respiration by oxygen and nitric oxide. *Ann N Y Acad Sci* 899: 121–135, 2000.
46. Brady NR, Hamacher-Brady A, Westerhoff HV, and Gottlieb RA. A wave of reactive oxygen species (ROS)-induced ROS release in a sea of excitable mitochondria. *Antioxid Redox Signal* 8: 1651–1665, 2006.
47. Brand MD. The proton leak across the mitochondrial inner membrane. *Biochim Biophys Acta* 1018: 128–133, 1990.
48. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, and Parker N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. *Free Radic Biol Med* 37: 755–767 [review], 2004.

49. Brand MD, Chien LF, Ainscow EK, Rolfe DF, and Porter RK. The causes and functions of mitochondrial proton leak. *Biochim Biophys Acta* 1187: 132–139, 1994.
50. Brand MD, Chien LF, and Dioloz P. Experimental discrimination between proton leak and redox slip during mitochondrial electron transport. *Biochem J* 297: 27–29, 1994.
51. Brandes R and Bers DM. Analysis of the mechanisms of mitochondrial NADH regulation in cardiac trabeculae. *Biophys J* 77: 1666–1682, 1999.
52. Brandes R and Bers DM. Intracellular Ca²⁺ increases the mitochondrial NADH concentration during elevated work in intact cardiac muscle. *Circ Res* 80: 82–87, 1997.
53. Broekemeier KM, Klocek CK, and Pfeiffer DR. Proton selective substrate of the mitochondrial permeability transition pore: regulation by the redox state of the electron transport chain. *Biochemistry* 37: 13059–13065, 1998.
54. Brookes P and Darley-Usmar VM. Hypothesis: the mitochondrial NO* signaling pathway, and the transduction of nitrosative to oxidative cell signals: an alternative function for cytochrome c oxidase. *Free Radic Biol Med* 32: 370–374, 2002.
55. Brookes PS. Mitochondrial H⁺ leak and ROS generation: an odd couple. *Free Radic Biol Med* 38: 12–23 [review], 2005.
56. Brookes PS, Freeman RS, and Barone MC. A shortcut to mitochondrial signaling and pathology: a commentary on “Nonenzymatic formation of succinate in mitochondria under oxidative stress”. *Free Radic Biol Med* 41: 41–45, 2006.
57. Brookes PS, Levonen AL, Shiva S, Sarti P, and Darley-Usmar VM. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. *Free Radic Biol Med* 33: 755–764, 2002.
58. Brookes PS, Shiva S, Patel RP, and Darley-Usmar VM. Measurement of mitochondrial respiratory thresholds and the control of respiration by nitric oxide. *Methods Enzymol* 359: 305–319, 2002.
59. Brookes PS, Yoon Y, Robotham JL, Anders MW, and Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *Am J Physiol Cell Physiol* 287: C817–C833 [review], 2004.
60. Brown GC and Brand MD. On the nature of the mitochondrial proton leak. *Biochim Biophys Acta* 1059: 55–62, 1991.
61. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell Metab* 1: 409–414, 2005.
62. Bulteau AL, Ikeda-Saito M, and Szwedda LI. Redoxdependent modulation of aconitase activity in intact mitochondria. *Biochemistry* 42: 14846–14855, 2003.

63. Butler J, Jayson GG, and Swallow AJ. The reaction between the superoxide anion radical and cytochrome c. *Biochim Biophys Acta* 408: 215–222, 1975.
64. Cadenas E and Boveris A. Enhancement of hydrogen peroxide formation by protophores and ionophores in antimycin- supplemented mitochondria. *Biochem J* 188: 31–37, 1980.
65. Cadenas E, Boveris A, Ragan CI, and Stoppani AO. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. *Arch Biochem Biophys* 180: 248–257, 1977.
66. Cadenas E and Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med* 29: 222–230 [review], 2000.
67. Cadenas S, Buckingham JA, St-Pierre J, Dickinson K, Jones RB, and Brand MD. AMP decreases the efficiency of skeletal-muscle mitochondria. *Biochem J* 351: 307–311, 2000.
68. Cai J and Jones DP. Superoxide in apoptosis: mitochondrial generation triggered by cytochrome c loss. *J Biol Chem* 273: 11401–11404, 1998.
69. Cairns CB, Ferroggiaro AA, Walther JM, Harken AH, and Banerjee A. Postischemic administration of succinate reverses the impairment of oxidative phosphorylation after cardiac ischemia and reperfusion injury. *Circulation* 96: II–260–265, 1997.
70. Camara A, Aldakkak M, Heisner JS, Rhodes SS, Riess ML, An J, Heinen A, and Stowe DF. ROS scavenging before 278C ischemia protects hearts and reduces mitochondrial ROS, Ca²⁺ overload, and changes in redox state. *Am J Physiol Cell Physiol* 292: C2021–C2031, 2007.
71. Camara AK, Riess ML, Kevin LG, Novalija E, and Stowe DF. Hypothermia augments reactive oxygen species detected in the guinea pig isolated perfused heart. *Am J Physiol Heart Circ Physiol* 286: H1289–H1299, 2004.
72. Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, and Camello PJ. Mitochondrial reactive oxygen species and Ca²⁺ signaling. *Am J Physiol Cell Physiol* 291: C1082–C1088 [review], 2006.
73. Campbell DL, Stamler JS, and Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes: dual mechanism regulation by nitric oxide and S-nitrosothiols. *J Gen Physiol* 108: 277–293, 1996.
74. Cancherini DV, Queliconi BB, and Kowaltowski AJ. Pharmacological and physiological stimuli do not promote Ca²⁺-sensitive K⁺ channel activity in isolated heart mitochondria. *Cardiovasc Res* 73: 720–728, 2007.
75. Cannon B, Shabalina IG, Kramarova TV, Petrovic N, and Nedergaard J. Uncoupling proteins: a role in protection against reactive oxygen species—or not? *Biochim Biophys Acta* 1757: 449–458 [review], 2006.

76. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. [Review]. *J Cereb Blood Flow Metab* 21: 2–14, 2001.
77. Chance B, Sies H, and Boveris A. Hydroperoxide metabolism in mammalian organs. *Physiol Rev* 59: 527–605 [review], 1979.
78. Chandel NS, Budinger GR, Choe SH, and Schumacker PT. Cellular respiration during hypoxia: role of cytochrome oxidase as the oxygen sensor in hepatocytes. *J Biol Chem* 272: 18808–18816, 1997.
79. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. *Proc Natl Acad Sci USA* 95: 11715–11720, 1998.
80. Chandel NS and Schumacker PT. Cellular oxygen sensing by mitochondria: old questions, new insight. *J Appl Physiol* 88: 1880–1889 [review], 2000.
81. Chen Q, Camara AK, Stowe DF, Hoppel CL, and Lesnefsky EJ. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion [review]. *Am J Physiol Cell Physiol* 292: C137–C147 [review], 2007.
82. Chen Q, Hoppel CL, and Lesnefsky EJ. Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria. *J Pharmacol Exp Ther* 316: 200–207, 2006.
83. Chen Q and Lesnefsky EJ. Depletion of cardiolipin and cytochrome c during ischemia increases hydrogen peroxide production from the electron transport chain. *Free Radic Biol Med* 40: 976–982, 2006.
84. Chen Q, Moghaddas S, Hoppel CL, and Lesnefsky EJ. Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. *Am J Physiol Cell Physiol* 294: C460–C466, 2008.
85. Chen Q, Moghaddas S, Hoppel CL, and Lesnefsky EJ. Reversible blockade of electron transport during ischemia protects mitochondria and decreases myocardial injury following reperfusion. *J Pharmacol Exp Ther* 319: 1405–1412, 2006.
86. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, and Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. *J Biol Chem* 278: 36027–36031, 2003.
87. Chipuk JE, Bouchier-Hayes L, and Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. *Cell Death Differ* 13: 1396–1402, 2006.
88. Choksi KB, Boylston WH, Rabek JP, Widger WR, and Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. *Biochim Biophys Acta* 1688: 95–101, 2004.
89. Clementi E, Brown GC, Foxwell N, and Moncada S. On the mechanism by which vascular endothelial cells regulate their oxygen consumption. *Proc Natl Acad Sci U S A* 96: 1559–1562, 1999.

90. Cohen MV, Baines CP, and Downey JM. Ischemic preconditioning: from adenosine receptor to K_{ATP} channel. *Annu Rev Physiol* 62: 79–109, 2000.
91. Collins TJ, Berridge MJ, Lipp P, and Bootman MD. Mitochondria are morphologically and functionally heterogeneous within cells. *EMBO J* 21: 1616–1627, 2002.
92. Cooper CE, Patel RP, Brookes PS, and Darley-Usmar VM. Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species. *Trends Biochem Sci* 27: 489–492, 2002.
93. Cortassa S, Aon MA, Winslow RL, and O'Rourke B. A mitochondrial oscillator dependent on reactive oxygen species. *Biophys J* 87: 2060–2073, 2004.
94. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, and Garlid KD. The mechanism by which the mitochondrial ATP-sensitive K^+ channel opening and H_2O_2 inhibit the mitochondrial permeability transition. *J Biol Chem* 281: 20801–20808, 2006.
95. Costa AD, Quinlan CL, Andrukhiv A, West IC, Jaburek M, and Garlid KD. The direct physiological effects of mito K_{ATP} opening on heart mitochondria. *Am J Physiol Heart Circ Physiol* 290: H406–H415, 2006.
96. Covian R and Trumpower BL. Regulatory interactions between ubiquinol oxidation and ubiquinone reduction sites in the dimeric cytochrome bc_1 complex. *J Biol Chem* 281: 30925–30932, 2006.
97. Crofts AR, Barquera B, Gennis RB, Kuras R, Guergova-Kuras M, and Berry EA. Mechanism of ubiquinol oxidation by the bc_1 complex: different domains of the quinol binding pocket and their role in the mechanism and binding of inhibitors. *Biochemistry* 38: 15807–15826, 1999.
98. Crofts AR, Guergova-Kuras M, Huang L, Kuras R, Zhang Z, and Berry EA. Mechanism of ubiquinol oxidation by the bc_1 complex: role of the iron sulfur protein and its mobility. *Biochemistry* 38: 15791–15806, 1999.
99. Crofts AR, Hong S, Ugulava N, Barquera B, Gennis R, Guergova-Kuras M, and Berry EA. Pathways for proton release during ubihydroquinone oxidation by the bc_1 complex. *Proc Natl Acad Sci U S A* 96: 10021–10026, 1999.
100. da Silva MM, Sartori A, Belisle E, and Kowaltowski AJ. Ischemic preconditioning inhibits mitochondrial respiration, increases H_2O_2 release, and enhances K^+ transport. *Am J Physiol Heart Circ Physiol* 285: H154–H162, 2003.
101. Das DK, Engelman RM, and Maulik N. Oxygen free radical signaling in ischemic preconditioning. *Ann N Y Acad Sci* 874: 49–65, 1999.
102. Das DK, Maulik N, Sato M, and Ray PS. Reactive oxygen species function as second messenger during ischemic preconditioning of heart. *Mol Cell Biochem* 196: 59–67, 1999.

103. Das M, Parker JE, and Halestrap AP. Matrix volume measurements challenge the existence of diazoxide/glibenclamide-sensitive K_{ATP} channels in rat mitochondria. *J Physiol* 547: 893–902, 2003.
104. De Grey AD. HO₂*: the forgotten radical. *DNA Cell Biol* 21: 251–257, 2002.
105. Debska G, Kicinska A, Skalska J, Szewczyk A, May R, Elger CE, and Kunz WS. Opening of potassium channels modulates mitochondrial function in rat skeletal muscle. *Biochim Biophys Acta* 1556: 97–105, 2002.
106. Delgado-Esteban M, Martin-Zanca D, Andres-Martin L, Almeida A, and Bolanos JP. Inhibition of PTEN by peroxynitrite activates the phosphoinositide-3-kinase/Akt neuroprotective signaling pathway. *J Neurochem* 102: 194–205, 2007.
107. Demin OV, Kholodenko BN, and Skulachev VP. A model of O₂^{•-} generation in the complex III of the electron transport chain. *Mol Cell Biochem* 184: 21–33, 1998.
108. Denton RM, McCormack JG, and Edgell NJ. Role of calcium ions in the regulation of intramitochondrial metabolism: effects of Na⁺, Mg²⁺ and ruthenium red on the Ca²⁺-stimulated oxidation of oxoglutarate and on pyruvate dehydrogenase activity in intact rat heart mitochondria. *Biochem J* 190: 107–117, 1980.
109. Di Lisa F, Canton M, Menabo R, Dodoni G, and Bernardi P. Mitochondria and reperfusion injury: the role of permeability transition. *Basic Res Cardiol* 98: 235–241, 2003.
110. Di Lisa F, Menabo R, Canton M, Barile M, and Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD⁺ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. *J Biol Chem* 276: 2571–2575, 2001.
111. Dikalov S, Griendling KK, and Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. *Hypertension* 49: 717–727, 2007.
112. Doughan AK, Harrison DG, and Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. *Circ Res* 102: 488–496, 2008.
113. Droge W. Free radicals in the physiological control of cell function. *Physiol Rev* 82: 47–95 [review], 2002.
114. Dudkina NV, Sunderhaus S, Boekema EJ, and Braun HP. The higher level of organization of the oxidative phosphorylation system: mitochondrial supercomplexes. *J Bioenerg Biomembr* 40: 419–424, 2008.
115. Duranteau J, Chandel NS, Kulisz A, Shao Z, and Schumacker PT. Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes. *J Biol Chem* 273: 11619–11624, 1998.

116. Echtay KS, Esteves TC, Pakay JL, Jekabsons MB, Lambert AJ, Portero-Otin M, Pamplona R, Vidal-Puig AJ, Wang S, Roebuck SJ, and Brand MD. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. *EMBO J* 22: 4103–4110, 2003.
117. Echtay KS, Murphy MP, Smith RA, Talbot DA, and Brand MD. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side: studies using targeted antioxidants. *J Biol Chem* 277: 47129–47135, 2002.
118. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, and Huang TT. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. *Oncogene* 24: 367–380, 2005.
119. Erusalimsky JD and Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. *Arterioscler Thromb Vasc Biol* 27: 2524–2531, 2007.
120. Facundo HT, Carreira RS, de Paula JG, Santos CC, Ferranti R, Laurindo FR, and Kowaltowski AJ. Ischemic preconditioning requires increases in reactive oxygen release independent of mitochondrial K⁺ channel activity. *Free Radic Biol Med* 40: 469–479, 2006.
121. Fedotcheva NI, Sokolov AP, and Kondrashova MN. Nonenzymatic formation of succinate in mitochondria under oxidative stress. *Free Radic Biol Med* 41: 56–64, 2006.
122. Fleury C, Mignotte B, and Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. *Biochimie* 84: 131–141 [review], 2002.
123. Flitter WD. Free radicals and myocardial reperfusion injury. *Br Med Bull* 49: 545–555 [review], 1993.
124. Forbes RA, Steenbergen C, and Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. *Circ Res* 88: 802–809, 2001.
125. Fraga CG, Shigenaga MK, Park JW, Degan P, and Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. *Proc Natl Acad Sci U S A* 87: 4533–4537, 1990.
126. Fruehauf JP and Meyskens FL Jr. Reactive oxygen species: a breath of life or death? *Clin Cancer Res* 13: 789–794 [review], 2007.
127. Galindo MF, Jordan J, Gonzalez-Garcia C, and Cena V. Reactive oxygen species induce swelling and cytochrome c release but not transmembrane depolarization in isolated rat brain mitochondria. *Br J Pharmacol* 139: 797–804, 2003.
128. Garcia-Nogales P, Almeida A, and Bolanos JP. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis: a key role for glucose-6-phosphate dehydrogenase activity in neuroprotection. *J Biol Chem* 278: 864–874, 2003.

129. Garlick PB, Davies MJ, Hearse DJ, and Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. *Circ Res* 61: 757–760, 1987.
130. Garlid KD. Opening mitochondrial K_{ATP} in the heart: what happens, and what does not happen. *Basic Res Cardiol* 95: 275–279 [short review], 2000.
131. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, and Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K^+ channel in cardiac function and cardioprotection. *Biochim Biophys Acta* 1606: 1–21 [review], 2003.
132. Garlid KD, Jaburek M, Jezek P, and Varecha M. How do uncoupling proteins uncouple? [short review]. *Biochim Biophys Acta* 1459: 383–389, 2000.
133. Garlid KD and Paucek P. Mitochondrial potassium transport: the K^+ cycle. *Biochim Biophys Acta* 1606: 23–41 [review], 2003.
134. Genova ML, Pich MM, Biondi A, Bernacchia A, Falasca A, Bovina C, Formiggini G, Parenti Castelli G, and Lenaz G. Mitochondrial production of oxygen radical species and the role of coenzyme Q as an antioxidant. *Exp Biol Med (Maywood)* 228: 506–513, 2003.
135. Genova ML, Ventura B, Giuliano G, Bovina C, Formiggini G, Parenti Castelli G, and Lenaz G. The site of production of superoxide radical in mitochondrial complex I is not a bound ubiquinone but presumably iron-sulfur cluster N2. *FEBS Lett* 505: 364–368, 2001.
136. Ghafourifar P, Asbury ML, Joshi SS, and Kincaid ED. Determination of mitochondrial nitric oxide synthase activity. *Methods Enzymol* 396: 424–444, 2005.
137. Ghafourifar P and Cadenas E. Mitochondrial nitric oxide synthase. *Trends Pharmacol Sci* 26: 190–195, 2005.
138. Gille L and Nohl H. The ubiquinol/bc1 redox couple regulates mitochondrial oxygen radical formation. *Arch Biochem Biophys* 388: 34–38, 2001.
139. Giulivi C, Poderoso JJ, and Boveris A. Production of nitric oxide by mitochondria. *J Biol Chem* 273: 11038–11043, 1998.
140. Golden TR and Melov S. Mitochondrial DNA mutations, oxidative stress, and aging. *Mech Ageing Dev* 122: 1577–1589 [review], 2001.
141. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 86: 494–501, 2000.
142. Grishko V, Solomon M, Wilson GL, LeDoux SP, and Gillespie MN. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. *Am J Physiol Lung Cell Mol Physiol* 280: L1300–L1308, 2001.
143. Guo J and Lemire BD. The ubiquinone-binding site of the

- Saccharomyces cerevisiae succinate-ubiquinone oxidoreductase is a source of superoxide. *J Biol Chem* 278: 47629–47635, 2003.
144. Gutteridge JM. Superoxide-dependent formation of hydroxyl radicals from ferric-complexes and hydrogen peroxide: an evaluation of fourteen iron chelators. *Free Radic Res Commun* 9: 119–125, 1990.
 145. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. *Cell Metab* 1: 401–408, 2005.
 146. Guzy RD and Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. *Exp Physiol* 91: 807–819 [review], 2006.
 147. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. *Science* 302: 1975–1978, 2003.
 148. Hak JB, Van Beek JH, Eijgelshoven MH, and Westerhof N. Mitochondrial dehydrogenase activity affects adaptation of cardiac oxygen consumption to demand. *Am J Physiol* 264: H448–H453, 1993.
 149. Halestrap AP. Regulation of mitochondrial metabolism through changes in matrix volume. *Biochem Soc Trans* 22: 522–529, 1994.
 150. Halestrap AP. The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism. *Biochim Biophys Acta* 973: 355–382, 1989.
 151. Halliwell B, Gutteridge JMC. Free radical in biology and medicine. 3rd ed. New York: Oxford University Press, pp 936, 1999.
 152. Han D, Williams E, and Cadenas E. Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. *Biochem J* 353: 411–416, 2001.
 153. Handschin C and Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. *Nature* 454: 463–469, 2008.
 154. Hanley PJ and Daut J. K_{ATP} channels and preconditioning: a re-examination of the role of mitochondrial K_{ATP} channels and an overview of alternative mechanisms. *J Mol Cell Cardiol* 39: 17–50, 2005.
 155. Hanley PJ, Gopalan KV, Lareau RA, Srivastava DK, von Meltzer M, and Daut J. Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels. *J Physiol* 547: 387–393, 2003.
 156. Hanley PJ, Mickel M, Loffler M, Brandt U, and Daut J. K_{ATP} channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart. *J Physiol* 542: 735–741, 2002.
 157. Hardy L, Clark JB, Darley-Usmar VM, Smith DR, and Stone D. Reoxygenation-dependent decrease in mitochondrial NADH:CoQ

- reductase (complex I) activity in the hypoxic/reoxygenated rat heart. *Biochem J* 274: 133–137, 1991.
158. Heinen A, Aldakkak M, Stowe DF, Rhodes SS, Riess ML, Varadarajan SG, and Camara AK. Reverse electron flow-induced ROS production is attenuated by activation of mitochondrial Ca²⁺-sensitive K⁺ channels. *Am J Physiol Heart Circ Physiol* 293: H1400–H1407, 2007.
 159. Heinen A, Camara AK, Aldakkak M, Rhodes SS, Riess ML, and Stowe DF. Mitochondrial Ca²⁺-induced K⁺ influx increases respiration and enhances ROS production while maintaining membrane potential. *Am J Physiol Cell Physiol* 292: C148–C156, 2007.
 160. Herrero A and Barja G. Localization of the site of oxygen radical generation inside the complex I of heart and nonsynaptic brain mammalian mitochondria. *J Bioenerg Biomembr* 32: 609–615, 2000.
 161. Hoffman DL, Salter JD, and Brookes PS. Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling. *Am J Physiol Heart Circ Physiol* 292: H101–108, 2007.
 162. Holmuhamedov EL, Jahangir A, Oberlin A, Komarov A, Colombini M, and Terzic A. Potassium channel openers are uncoupling protonophores: implication in cardioprotection. *FEBS Lett* 568: 167–170, 2004.
 163. Hool LC. Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels. *Clin Exp Pharmacol Physiol* 33: 146–151 [review], 2006.
 164. Hool LC and Arthur PG. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca²⁺ channel to beta-adrenergic receptor stimulation in cardiac myocytes. *Circ Res* 91: 601–609, 2002.
 165. Huang LE, Gu J, Schau M, and Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O₂-dependent degradation domain via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci U S A* 95: 7987–7992, 1998.
 166. Huang TT, Carlson EJ, Gillespie AM, Shi Y, and Epstein CJ. Ubiquitous overexpression of CuZn superoxide dismutase does not extend life span in mice. *J Gerontol A Biol Sci Med Sci* 55: B5–B9, 2000.
 167. Humphries KM and Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. *Biochemistry* 37: 15835–15841, 1998.
 168. Humphries KM, Yoo Y, and Szweda LI. Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. *Biochemistry* 37: 552–557, 1998.

169. Huser J and Blatter LA. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. *Biochem J* 343: 311–317, 1999.
170. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. *Circ Res* 85: 357–363, 1999.
171. Inarrea P, Moini H, Han D, Rettori D, Aguilo I, Alava MA, Iturralde M, and Cadenas E. Mitochondrial respiratory chain and thioredoxin reductase regulate intermembrane Cu,Zn-superoxide dismutase activity: implications for mitochondrial energy metabolism and apoptosis. *Biochem J* 405: 173–179, 2007.
172. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. [Review]. *Circ Res* 87: 179–183, 2000.
173. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr. HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science* 292: 464–468, 2001.
174. Jaburek M and Garlid KD. Reconstitution of recombinant uncoupling proteins: UCP1, -2, and -3 have similar affinities for ATP and are unaffected by coenzyme Q10. *J Biol Chem* 278: 25825–25831, 2003.
175. Jezek P, Engstova H, Zackova M, Vercesi AE, Costa AD, Arruda P, and Garlid KD. Fatty acid cycling mechanism and mitochondrial uncoupling proteins. *Biochim Biophys Acta* 1365: 319–327, 1998.
176. Jezek P, Zackova M, Ruzicka M, Skobisova E, and Jaburek M. Mitochondrial uncoupling proteins: facts and fantasies. *Physiol Res* 53(suppl 1): S199–S211, 2004.
177. Jiang BH, Semenza GL, Bauer C, and Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O₂ tension. *Am J Physiol* 271: C1172–C1180, 1996.
178. Jiang MT, Ljubkovic M, Nakae Y, Shi Y, Kwok WM, Stowe DF, and Bosnjak ZJ. Characterization of human cardiac mitochondrial ATP-sensitive potassium channel and its regulation by phorbol ester in vitro. *Am J Physiol Heart Circ Physiol* 290: H1770–H1776, 2006.
179. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. *Biochim Biophys Acta* 1604: 77–94, 2003.
180. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. *Biochem Biophys Res Commun* 338: 627–638, 2005.
181. Kevin LG, Camara AK, Riess ML, Novalija E, and Stowe DF. Ischemic preconditioning alters real-time measure of O₂ radicals in intact hearts

- with ischemia and reperfusion. *Am J Physiol Heart Circ Physiol* 284: H566–H574, 2003.
182. Kevin LG, Novalija E, Riess ML, Camara AK, Rhodes SS, and Stowe DF. Sevoflurane exposure generates superoxide but leads to decreased superoxide during ischemia and reperfusion in isolated hearts. *Anesth Analg* 96: 949–955, 2003.
 183. Kevin LG, Novalija E, and Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. *Anesth Analg* 101: 1275–1287 [review], 2005.
 184. Kietzmann T, Fandrey J, and Acker H. Oxygen radicals as messengers in oxygen-dependent gene expression. *News Physiol Sci* 15: 202–208, 2000.
 185. Kietzmann T and Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. *Semin Cell Dev Biol* 16: 474–486, 2005.
 186. Kim JS, Jin Y, and Lemasters JJ. Reactive oxygen species, but not Ca^{2+} overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. *Am J Physiol Heart Circ Physiol* 290: H2024–H2034, 2006.
 187. Kim JS, Qian T, and Lemasters JJ. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. *Gastroenterology* 124: 494–503, 2003.
 188. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Suzuki T, Maeta H, and Abe Y. Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. *Hypertension* 45: 860–866, 2005.
 189. Koehler CM, Beverly KN, and Leverich EP. Redox pathways of the mitochondrion. *Antioxid Redox Signal* 8: 813–822 [review], 2006.
 190. Korshunov SS, Korkina OV, Ruuge EK, Skulachev VP, and Starkov AA. Fatty acids as natural uncouplers preventing generation of $\text{O}_2^{\bullet-}$ and H_2O_2 by mitochondria in the resting state. *FEBS Lett* 435: 215–218, 1998.
 191. Korshunov SS, Skulachev VP, and Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. *FEBS Lett* 416: 15–18, 1997.
 192. Korzeniewski B. Regulation of oxidative phosphorylation through parallel activation. *Biophys Chem* 129: 93–110, 2007.
 193. Korzeniewski B, Noma A, and Matsuoka S. Regulation of oxidative phosphorylation in intact mammalian heart in vivo. *Biophys Chem* 116: 145–157, 2005.
 194. Kowaltowski AJ, Castilho RF, and Vercesi AE. Ca^{2+} -induced mitochondrial membrane permeabilization: role of coenzyme Q redox state. *Am J Physiol* 269: C141–C147, 1995.

195. Kowaltowski AJ, Seetharaman S, Paucek P, and Garlid KD. Bioenergetic consequences of opening the ATP-sensitive K⁺ channel of heart mitochondria. *Am J Physiol Heart Circ Physiol* 280: H649–H657, 2001.
196. Kroll SL and Czyzyk-Krzeska MF. Role of H₂O₂ and emecontaining O₂ sensors in hypoxic regulation of tyrosine hydroxylase gene expression. *Am J Physiol* 274: C167–C174, 1998.
197. Ksenzenko M, Konstantinov AA, Khomutov GB, Tikhonov AN, and Ruuge EK. Effect of electron transfer inhibitors on superoxide generation in the cytochrome bc1 site of the mitochondrial respiratory chain. *FEBS Lett* 155: 19–24, 1983.
198. Kukreja RC. Mechanism of reactive oxygen species generation after opening of mitochondrial K_{ATP} channels. *Am J Physiol Heart Circ Physiol* 291: H2041–H2043, 2006.
199. Kushnareva Y, Murphy AN, and Andreyev A. Complex I mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)⁺ oxidation-reduction state. *Biochem J* 368: 545–553, 2002.
200. Lambert AJ and Brand MD. Inhibitors of the quinonebinding site allow rapid superoxide production from mitochondrial NADH:ubiquinone oxidoreductase (complex I). *J Biol Chem* 279: 39414–39420, 2004.
201. Lambert AJ and Brand MD. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. *Biochem J* 382: 511–517, 2004.
202. Landar A and Darley-Usmar VM. Nitric oxide and cell signaling: modulation of redox tone and protein modification. *Amino Acids* 25: 313–321 [review], 2003.
203. Lander HM. An essential role for free radicals and derived species in signal transduction [review]. *FASEB J* 11: 118–124, 1997.
204. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, and Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. *Proc Natl Acad Sci USA* 93: 9782–9787, 1996.
205. Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, and Vanden Hoek TL. ROS and NO trigger early preconditioning: relationship to mitochondrial K_{ATP} channel. *Am J Physiol Heart Circ Physiol* 284: H299–H308, 2003.
206. Lecarpentier Y. Physiological role of free radicals in skeletal muscles. *J Appl Physiol* 103: 1917–1918 [review], 2007.
207. Lee HC and Wei YH. Mitochondrial role in life and death of the cell. *J Biomed Sci* 7: 2–15 [review], 2000.
208. Lee JW, Bae SH, Jeong JW, Kim SH, and Kim KW. Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions. *Exp Mol Med* 36: 1–12, 2004.

209. Lefer DJ and Granger DN. Oxidative stress and cardiac disease. *Am J Med* 109: 315–323 [review], 2000.
210. Lenaz G, Bovina C, D'Aurelio M, Fato R, Formiggini G, Genova ML, Giuliano G, Merlo Pich M, Paolucci U, Parenti Castelli G, and Ventura B. Role of mitochondria in oxidative stress and aging. *Ann N Y Acad Sci* 959: 199–213, 2002.
211. Lenaz G, Landi L, Cabrini L, Pasquali P, Sechi AM, and Ozawa T. On the sidedness of the ubiquinone redox cycle: kinetic studies in mitochondrial membranes. *Biochem Biophys Res Commun* 85: 1047–1053, 1978.
212. Lesnefsky EJ, Gudz TI, Migita CT, Ikeda-Saito M, Hassan MO, Turkaly PJ, and Hoppel CL. Ischemic injury to mitochondrial electron transport in the aging heart: damage to the iron-sulfur protein subunit of electron transport complex III. *Arch Biochem Biophys* 385: 117–128, 2001.
213. Lesnefsky EJ, Slabe TJ, Stoll MS, Minkler PE, and Hoppel CL. Myocardial ischemia selectively depletes cardiolipin in rabbit heart subsarcolemmal mitochondria. *Am J Physiol Heart Circ Physiol* 280: H2770–H2778, 2001.
214. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, and Epstein CJ. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 11: 376–381, 1995.
215. Liu SS. Cooperation of a "reactive oxygen cycle" with the Q cycle and the proton cycle in the respiratory chain: superoxide generating and cycling mechanisms in mitochondria. *J Bioenerg Biomembr* 31: 367–376, 1999.
216. Liu Y, Fiskum G, and Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. *J Neurochem* 80: 780–787, 2002.
217. Liu Y and O'Rourke B. Opening of mitochondrial K_{ATP} channels triggers Cardioprotection: are reactive oxygen species involved? *Circ Res* 88: 750–752, 2001.
218. Loschen G, Flohe L, and Chance B. Respiratory chain linked H_2O_2 production in pigeon heart mitochondria. *FEBS Lett* 18: 261–264, 1971.
219. Ludwig B, Bender E, Arnold S, Huttemann M, Lee I, and Kadenbach B. Cytochrome C oxidase and the regulation of oxidative phosphorylation. *Chem Biochem* 2: 392–403, 2001.
220. Luetjens CM, Bui NT, Sengpiel B, Munstermann G, Poppe M, Krohn AJ, Bauerbach E, Krieglstein J, and Prehn JH. Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. *J Neurosci* 20: 5715–5723, 2000.
221. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c

- impairs cellular oxygen sensing and hypoxic HIF- α activation. *Cell Metab* 1: 393–399, 2005.
222. Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, and Moncada S. Regulation of hypoxia-inducible factor-1 α by nitric oxide through mitochondria-dependent and -independent pathways. *Biochem J* 376: 537–544, 2003.
223. Maulik N, Watanabe M, Zu YL, Huang CK, Cordis GA, Schley JA, and Das DK. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. *FEBS Lett* 396: 233–237, 1996.
224. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, and Das DK. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. *Am J Physiol* 275: H1857–H1864, 1998.
225. McBride HM, Neuspiel M, and Wasiak S. Mitochondria: more than just a powerhouse. *Curr Biol* 16: R551–R560, 2006.
226. McCormack JG and Denton RM. Mitochondrial Ca^{2+} transport and the role of intramitochondrial Ca^{2+} in the regulation of energy metabolism. *Dev Neurosci* 15: 165–173, 1993.
227. McCormack JG and Denton RM. Role of calcium ions in the regulation of intramitochondrial metabolism: properties of the Ca^{2+} -sensitive dehydrogenases within intact uncoupled mitochondria from the white and brown adipose tissue of the rat. *Biochem J* 190: 95–105, 1980.
228. McCormack JG and Denton RM. The role of intramitochondrial Ca^{2+} in the regulation of oxidative phosphorylation in mammalian tissues. *Biochem Soc Trans* 21: 793–799, 1993.
229. Mitchell P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. *Biol Rev Camb Philos Soc* 41: 445–502, 1966.
230. Mitchell P. Proton current flow in mitochondrial systems. *Nature* 214: 1327–1328, 1967.
231. Mitchell P. The protonmotive Q cycle: a general formulation. *FEBS Lett* 59: 137–139, 1975.
232. Miyata H, Silverman HS, Sollott SJ, Lakatta EG, Stern MD, and Hansford RG. Measurement of mitochondrial free Ca^{2+} concentration in living single rat cardiac myocytes. *Am J Physiol* 261: H1123–H1134, 1991.
233. Moudgil R, Michelakis ED, and Archer SL. Hypoxic pulmonary vasoconstriction. *J Appl Physiol* 98: 390–403, 2005.
234. Muller FL, Lustgarten MS, Jang Y, Richardson A, and Van Remmen H. Trends in oxidative aging theories. *Free Radic Biol Med* 43: 477–503 [review], 2007.
235. Muller FL, Song W, Liu Y, Chaudhuri A, Pieke-Dahl S, Strong R, Huang TT, Epstein CJ, Roberts LJ 2nd, Csete M, Faulkner JA, and Van Remmen H. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. *Free Radic Biol Med* 40: 1993–2004, 2006.

236. Murata M, Akao M, O'Rourke B, and Marban E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca^{2+} overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. *Circ Res* 89: 891–898, 2001.
237. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. *Circ Res* 94: 7–16, 2004.
238. Nadtochiy SM, Tompkins AJ, and Brookes PS. Different mechanisms of mitochondrial proton leak in ischaemia/reperfusion injury and preconditioning: implications for pathology and cardioprotection. *Biochem J* 395: 611–618, 2006.
239. Nakashima RA, Dordick RS, and Garlid KD. On the relative roles of Ca^{2+} and Mg^{2+} in regulating the endogenous K^+/H^+ exchanger of rat liver mitochondria. *J Biol Chem* 257: 12540–12545, 1982.
240. Naqui A, Chance B, and Cadenas E. Reactive oxygen intermediates in biochemistry. *Annu Rev Biochem* 55: 137–166, 1986.
241. Nedergaard J, Ricquier D, and Kozak LP. Uncoupling proteins: current status and therapeutic prospects. *EMBO Rep* 6: 917–921 [review], 2005.
242. Nemoto S, Takeda K, Yu ZX, Ferrans VJ, and Finkel T. Role for mitochondrial oxidants as regulators of cellular metabolism. *Mol Cell Biol* 20: 7311–7318, 2000.
243. Nicholls DG. Mitochondria and calcium signaling. *Cell Calcium* 38: 311–317 [review], 2005.
244. Nicholls DG. The physiological regulation of uncoupling proteins. *Biochim Biophys Acta* 1757: 459–466 [review], 2006.
245. Nohl H. Generation of superoxide radicals as byproduct of cellular respiration. *Ann Biol Clin (Paris)* 52: 199–204, 1994.
246. Nohl H, Gille L, and Staniek K. Intracellular generation of reactive oxygen species by mitochondria. *Biochem Pharmacol* 69: 719–723 [short review], 2005.
247. Novalija E, Kevin LG, Camara AK, Bosnjak ZJ, Kampine JP, and Stowe DF. Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade. *Anesthesiology* 99: 421–428, 2003.
248. Novalija E, Varadarajan SG, Camara AKS, An JZ, Chen Q, Riess ML, Hogg H, Stowe DF. Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts. *Am J Physiol Heart Circ Physiol* 283: H44–H52, 2002.
249. Nulton-Persson AC, Starke DW, Mieyal JJ, and Szweda LI. Reversible inactivation of alpha-ketoglutarate dehydrogenase in response to alterations in the mitochondrial glutathione status. *Biochemistry* 42: 4235–4242, 2003.

250. Nulton-Persson AC and Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. *J Biol Chem* 276: 23357–23361, 2001.
251. Ohnishi ST, Ohnishi T, Muranaka S, Fujita H, Kimura H, Uemura K, Yoshida K, and Utsumi K. A possible site of superoxide generation in the complex I segment of rat heart mitochondria. *J Bioenerg Biomembr* 37: 1–15, 2005.
252. Okun JG, Lummen P, and Brandt U. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase). *J Biol Chem* 274: 2625–2630, 1999.
253. Pai HV, Starke DW, Lesnefsky EJ, Hoppel CL, and Mielal JJ. What is the functional significance of the unique location of glutaredoxin 1 (GRx1) in the intermembrane space of mitochondria? *Antioxid Redox Signal* 9: 2027–2033, 2007.
254. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS, Heusch G, Cohen MV, and Downey JM. Opening of mitochondrial K_{ATP} channels triggers the preconditioned state by generating free radicals. *Circ Res* 87: 460–466, 2000.
255. Panov A, Dikalov S, Shalbuyeva N, Hemendinger R, Greenamyre JT, and Rosenfeld J. Species- and tissuespecific relationships between mitochondrial permeability transition and generation of ROS in brain and liver mitochondria of rats and mice. *Am J Physiol Cell Physiol* 292: C708–C718, 2007.
256. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, and Greenamyre JT. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. *J Biol Chem* 280: 42026–42035, 2005.
257. Paradies G, Petrosillo G, Pistolese M, Di Venosa N, Federici A, and Ruggiero FM. Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin. *Circ Res* 94: 53–59, 2004.
258. Paradies G, Petrosillo G, Pistolese M, and Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. *Gene* 286: 135–141, 2002.
259. Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron-Adele S, Garlid KD, and Dos Santos P. Sarcoplasmic ATP-sensitive potassium channel blocker HMR 1098 protects the ischemic heart: implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. *J Mol Cell Cardiol* 42: 631–642, 2007.
260. Petrosillo G, Casanova G, Matera M, Ruggiero FM, and Paradies G. Interaction of peroxidized cardiolipin with rat heart mitochondrial membranes: induction of permeability transition and cytochrome c release. *FEBS Lett* 580: 6311–6316, 2006.

261. Petrosillo G, Ruggiero FM, and Paradies G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. *FASEB J* 17: 2202–2208, 2003.
262. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, and Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* 14: 2231–2239, 2005.
263. Raha S, McEachern GE, Myint AT, and Robinson BH. Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. *Free Radic Biol Med* 29: 170–180, 2000.
264. Raineri I, Carlson EJ, Gacayan R, Carra S, Oberley TD, Huang TT, and Epstein CJ. Strain-dependent high-level expression of a transgene for manganese superoxide dismutase is associated with growth retardation and decreased fertility. *Free Radic Biol Med* 31: 1018–1030, 2001.
265. Rappaport L, Oliviero P, and Samuel JL. Cytoskeleton and mitochondrial morphology and function. *Mol Cell Biochem* 184: 101–105, 1998.
266. Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. *Exp Mol Med* 31: 53–59 [review], 1999.
267. Ricci JE, Gottlieb RA, and Green DR. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. *J Cell Biol* 160: 65–75, 2003.
268. Rich PR and Bonner WD. The sites of superoxide anion generation in higher plant mitochondria. *Arch Biochem Biophys* 188: 206–213, 1978.
269. Riess ML, Camara AK, Kevin LG, An J, and Stowe DF. Reduced reactive O₂ species formation and preserved mitochondrial NADH and [Ca²⁺] levels during short-term 17°C ischemia in intact hearts. *Cardiovasc Res* 61: 580–590, 2004.
270. Riess ML, Costa AD, Carlson R Jr, Garlid KD, Heinen A, and Stowe DF. Differential increase of mitochondrial matrix volume by sevoflurane in isolated cardiac mitochondria. *Anesth Analg* 106: 1049–1055, 2008.
271. Riess ML, Kevin LG, McCormick J, Jiang MT, Rhodes SS, and Stowe DF. Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in guinea pig isolated hearts. *Anesth Analg* 100: 46–53, 2005.
272. Riess ML, Stowe DF, and Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? *Am J Physiol Heart Circ Physiol* 286: H1603–H1607, 2004.
273. Robinson KM, Janes MS, Pehar M, Monette JS, Ross MF, Hagen TM, Murphy MP, and Beckman JS. Selective fluorescent imaging of

- superoxide in vivo using ethidiumbased probes. *Proc Natl Acad Sci U S A* 103: 15038–15043, 2006.
274. Rush JD and Koppenol WH. Oxidizing intermediates in the reaction of ferrous EDTA with hydrogen peroxide: reactions with organic molecules and ferrocytochrome c. *J Biol Chem* 261: 6730–6733, 1986.
275. Rush JD, Maskos Z, and Koppenol WH. Distinction between hydroxyl radical and ferryl species. *Methods Enzymol* 186: 148–156, 1990.
276. Saborido A, Soblechero L, and Megias A. Isolated respiring heart mitochondria release reactive oxygen species in states 4 and 3. *Free Radic Res* 39: 921–931, 2005.
277. Sadek HA, Humphries KM, Szweda PA, and Szweda LI. Selective inactivation of redox-sensitive mitochondrial enzymes during cardiac reperfusion. *Arch Biochem Biophys* 406: 222–228, 2002.
278. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. *Nature* 423: 769–773, 2003.
279. Schafer FQ and Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med* 30: 1191–1212, 2001.
280. Schriener SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, and Rabinovitch PS. Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science* 308: 1909–1911, 2005.
281. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- α prolyl hydroxylase. *Cancer Cell* 7: 77–85, 2005.
282. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. *Biochem Pharmacol* 59: 47–53, 2000.
283. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. *J Appl Physiol* 88: 1474–1480, 2000.
284. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. *Biochem J* 405: 1–9, 2007.
285. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. *J Clin Invest* 106: 809–812, 2000.
286. Semenza GL, Agani F, Feldser D, Iyer N, Kotch L, Laughner E, and Yu A. Hypoxia, HIF-1, and the pathophysiology of common human diseases. *Adv Exp Med Biol* 475: 123–130, 2000.
287. Shao Q, Matsubara T, Bhatt SK, and Dhalla NS. Inhibition of cardiac sarcolemma Na⁺-K⁺ ATPase by oxyradical generating systems. *Mol Cell Biochem* 147: 139–144, 1995.
288. Shigenaga MK, Aboujaoude EN, Chen Q, and Ames BN. Assays of oxidative DNA damage biomarkers 8-oxo-2'-deoxyguanosine and 8-

- oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. *Methods Enzymol* 234: 16–33, 1994.
289. Shigenaga MK, Hagen TM, and Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci U S A* 91: 10771–10778, 1994.
290. Simpson PJ and Lucchesi BR. Free radicals and myocardial ischemia and reperfusion injury. *J Lab Clin Med* 110: 13–30 [review], 1987.
291. Sipos I, Tretter L, and Adam-Vizi V. The production of reactive oxygen species in intact isolated nerve terminals is independent of the mitochondrial membrane potential. *Neurochem Res* 28: 1575–1581, 2003.
292. Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. *FEBS Lett* 423: 275–280, 1998.
293. Skulachev VP. Membrane-linked systems preventing superoxide formation. *Biosci Rep* 17: 347–366, 1997.
294. Skulachev VP. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. *Q Rev Biophys* 29: 169–202, 1996.
295. St-Pierre J, Buckingham JA, Roebuck SJ, and Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. *J Biol Chem* 277: 44784–44790, 2002.
296. Starkov AA and Fiskum G. Myxothiazol induces H₂O₂ production from mitochondrial respiratory chain. *Biochem Biophys Res Commun* 281: 645–650, 2001.
297. Starkov AA and Fiskum G. Regulation of brain mitochondrial H₂O₂ production by membrane potential and NAD(P)H redox state. *J Neurochem* 86: 1101–1107, 2003.
298. Stowe DF, Aldakkak M, Camara AKS, Riess ML, Heinen A, Varadarajan SG, Jiang MT. Cardiac mitochondrial preconditioning by big Ca²⁺-sensitive K⁺ channel opening requires superoxide radical generation. *Am J Physiol Heart Circ Physiol* 290: H434–H440, 2006.
299. Stowe DF and Riess ML. Reactive oxygen species and cardiac preconditioning: many questions remain. *Cardiovasc Drugs Ther* 18: 87–90 [short review], 2004.
300. Stuart JA, Cadenas S, Jekabsons MB, Roussel D, and Brand MD. Mitochondrial proton leak and the uncoupling protein 1 homologues. *Biochim Biophys Acta* 1504: 144–158, 2001.
301. Takeishi Y, Jalili T, Ball NA, and Walsh RA. Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated. *Circ Res* 85: 264–271, 1999.

302. Tay YM, Lim KS, Sheu FS, Jenner A, Whiteman M, Wong KP, and Halliwell B. Do mitochondria make nitric oxide? No? *Free Radic Res* 38: 591–599, 2004.
303. Thannickal VJ and Fanburg BL. Reactive oxygen species in cell signaling. *Am J Physiol Lung Cell Mol Physiol* 279: L1005–L1028 [review], 2000.
304. Tokube K, Kiyosue T, and Arita M. Effects of hydroxyl radicals on K_{ATP} channels in guinea-pig ventricular myocytes. *Pflugers Arch* 437: 155–157, 1998.
305. Tokube K, Kiyosue T, and Arita M. Openings of cardiac K_{ATP} channel by oxygen free radicals produced by xanthine oxidase reaction. *Am J Physiol* 271: H478–H489, 1996.
306. Tritto I, D'Andrea D, Eramo N, Scognamiglio A, De Simone C, Violante A, Esposito A, Chiariello M, and Ambrosio G. Oxygen radicals can induce preconditioning in rabbit hearts. *Circ Res* 80: 743–748, 1997.
307. Turrens JF. Mitochondrial formation of reactive oxygen species. *J Physiol* 552: 335–344 [review], 2003.
308. Turrens JF, Alexandre A, and Lehninger AL. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. *Arch Biochem Biophys* 237: 408–414, 1985.
309. Turrens JF, Beconi M, Barilla J, Chavez UB, and McCord JM. Mitochondrial generation of oxygen radicals during reoxygenation of ischemic tissues. *Free Radic Res Commun* 12–13: 681–689, 1991.
310. Turrens JF, Freeman BA, and Crapo JD. Hyperoxia increases H_2O_2 release by lung mitochondria and microsomes. *Arch Biochem Biophys* 217: 411–421, 1982.
311. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, and Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. *J Biol Chem* 274: 2234–2242, 1999.
312. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, and Monsalve M. PGC-1 α regulates the mitochondrial anti-oxidant defense system in vascular endothelial cells. *Cardiovasc Res* 66: 562–573, 2005.
313. van Beek JH, Tian X, Zuurbier CJ, de Groot B, van Echteld CJ, Eijgelshoven MH, and Hak JB. The dynamic regulation of myocardial oxidative phosphorylation: analysis of the response time of oxygen consumption. *Mol Cell Biochem* 184: 321–344, 1998.
314. van Beek JH, van Wijhe MH, Eijgelshoven MH, and Hak JB. Dynamic adaptation of cardiac oxidative phosphorylation is not mediated by simple feedback control. *Am J Physiol* 277: H1375–H1384, 1999.
315. van Montfort RL, Congreve M, Tisi D, Carr R, and Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. *Nature* 423: 773–777, 2003.

316. Vanden Hoek TL, Becker LB, Shao Z, Li C, and Schumacker PT. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. *J Biol Chem* 273: 18092–18098, 1998.
317. Vanden Hoek TL, Li C, Shao Z, Schumacker PT, and Becker LB. Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion. *J Mol Cell Cardiol* 29: 2571–2583, 1997.
318. Vanden Hoek TL, Shao Z, Li C, Schumacker PT, and Becker LB. Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes. *J Mol Cell Cardiol* 29: 2441–2450, 1997.
319. Ventura B, Genova ML, Bovina C, Formiggini G, and Lenaz G. Control of oxidative phosphorylation by complex I in rat liver mitochondria: implications for aging. *Biochim Biophys Acta* 1553: 249–260, 2002.
320. Verkhovskaya ML, Belevich N, Euro L, Wikstrom M, and Verkhovskiy MI. Real-time electron transfer in respiratory complex I. *Proc Natl Acad Sci U S A* 105: 3763–3767, 2008.
321. Vinogradov AD and Grivennikova VG. Generation of superoxide-radical by the NADH:ubiquinone oxidoreductase of heart mitochondria. *Biochemistry (Mosc)* 70: 120–127, 2005.
322. Voet D, Judith G. Voet JG, Pratt CW. *Fundamentals of biochemistry*. 2nd ed. New York: John Wiley and Sons, 2006.
323. von Harsdorf R, Li PF, and Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. *Circulation* 99: 2934–2941, 1999.
324. Votyakova TV and Reynolds IJ. ΔY_m -Dependent and independent production of reactive oxygen species by rat brain mitochondria. *J Neurochem* 79: 266–277, 2001.
325. Wang ZB, Li M, Zhao Y, and Xu JX. Cytochrome c is a hydrogen peroxide scavenger in mitochondria. *Protein Pept Lett* 10: 247–253, 2003.
326. Weir EK, Lopez-Barneo J, Buckler KJ, and Archer SL. Acute oxygen-sensing mechanisms. *N Engl J Med* 353: 2042–2055, 2005.
327. Weissmann N, Ebert N, Ahrens M, Ghofrani HA, Schermuly RT, Hanze J, Fink L, Rose F, Conzen J, Seeger W, and Grimminger F. Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs. *Am J Respir Cell Mol Biol* 29: 721–732, 2003.
328. Wolin MS, Ahmad M, and Gupte SA. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. *Am J Physiol Lung Cell Mol Physiol* 289: L159–L173 [review], 2005.

329. Wu F, Jeneson JA, and Beard DA. Oxidative ATP synthesis in skeletal muscle is controlled by substrate feedback. *Am J Physiol Cell Physiol* 292: C115–C124, 2007.
330. Wu J, Dunham WR, and Weiss B. Overproduction and physical characterization of SoxR, a [2Fe-2S] protein that governs an oxidative response regulon in *Escherichia coli*. *J Biol Chem* 270: 10323–10327, 1995.
331. Zhao H, Joseph J, Fales HM, Sokoloski EA, Levine RL, Vasquez-Vivar J, and Kalyanaraman B. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. *Proc Natl Acad Sci USA* 102: 5727–5732, 2005.
332. Zhao Y, Wang ZB, and Xu JX. Effect of cytochrome c on the generation and elimination of $O_2^{\bullet-}$ and H_2O_2 in mitochondria. *J Biol Chem* 278: 2356–2360, 2003.
333. Zhao Y and Xu JX. The operation of the alternative electronleak pathways mediated by cytochrome c in mitochondria. *Biochem Biophys Res Commun* 317: 980–987, 2004.
334. Zmijewski JW, Landar A, Watanabe N, Dickinson DA, Noguchi N, and Darley-Usmar VM. Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium. *Biochem Soc Trans* 33: 1385–1389, 2005.
335. Zoccarato F, Cavallini L, Bortolami S, and Alexandre A. Succinate modulation of H_2O_2 release at NADH:ubiquinone oxidoreductase (complex I) in brain mitochondria. *Biochem J* 406: 125–129, 2007.
336. Zorov DB, Filburn CR, Klotz LO, Zweier JL, and Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J Exp Med* 192: 1001–1014, 2000.

Fig.1.

Schema of electron transfer through respiratory chain with sites of ROS ($O_2^{\bullet-}$) generation at complexes I and III. Electron transfer is reversible, except at complex IV, and forward transfer results in extramatrix proton pumping at complexes I, III, and IV, with reentering of protons at complex V coupled to ATP synthesis. Succinate can lead to reverse electron transfer, reduction of NAD^+ to NADH, and $O_2^{\bullet-}$ generation at complex I. [Used with permission and modified from Batandier *et al.* (22)].




Fig. 2

(A) Sites of $O_2^{\bullet-}$ generation along electron-transport system with several respiratory inhibitors. (B) Diagram of electron-transport system with standard reduction potentials (E°) of mobile components and ΔE° where sufficient free energy is harvested to synthesize ATP.




Table 1.

Examples of Reactive Oxygen (Nitrogen, Chlorinating) Species

Radicals	Nonradicals
Superoxide, $O_2^{\bullet-}$	Hydrogen peroxide, H_2O_2
Ferryl, $Fe(IV) = O^{\bullet}$	Hypochlorous acid, HOCl
Peroxyl, RO^{\bullet}	Oxone, O_3
Alkoxy, RO^{\bullet}	Singlet oxygen, $^1\Delta_9O_2$
Nitric oxide, NO^{\bullet}	Peroxynitrite, $ONOO^-$
Hydroperoxyl, HO_2^{\bullet}	Peroxynitrous acid, $ONOOH$

Note that not all radicals ($O_2^{\bullet-}$) or nonradicals (H_2O_2) are highly reactive, whereas other radicals and nonradicals are highly reactive (HO_2^{\bullet} , $ONOOH$). Carbon-centered radicals (Cl_3C^{\bullet}), sulfur-centered radicals ($RS^{\bullet}/RSS^{\bullet}$), and nitrogen-centered radicals ($C_6H_5N = N^{\bullet}$) also exist (151).

Fig. 3

The products of superoxide ($O_2^{\bullet-}$) and their catalysts.




Fig. 4

EPR spectra indicating formation of $O_2^{\bullet-}$ (DMPO-OH signals) by mitochondria. The $O_2^{\bullet-}$ spin-trap DMPO and antimycin A (**B**) are necessary to observe the signals (Control; **A**), which are abolished by SOD (**C**). Succinate + antimycin A (**D**). [Reprinted with permission from Han *et al.* (152)].





Fig. 5

Representative traces of H₂O₂ emission rates (amplex red, HRP) during 10 mM succinate-supported respiration in guinea pig heart isolated mitochondria. H₂O₂ emission was abrogated (**A**) by adding 4 μM carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), a mitochondrial uncoupler, or by 4 μM rotenone (**B**), a complex I blocker. H₂O₂ emission during pyruvate (complex I substrate, 10 μM)-supported respiration (**C**). Catalase (300 U/ml) was added to scavenge the H₂O₂ generated, and 5 μM antimycin A (**AA**) was added to enhance the H₂O₂ generated at complex III. Note the lower rate of H₂O₂ emission with pyruvate than with succinate (reverse electron transfer). afu, arbitrary fluorescence units. Numbers are changes in afu/min. [Reprinted with permission from Heinen *et al.* (158)].



Antioxidants and Redox Signaling, Vol. 11, No. 6 (June 2009): pg. 1373-1414. DOI. This article is © Mary Ann Liebert, Inc. and permission has been granted for this version to appear in e-Publications@Marquette. Mary Ann Liebert, Inc. does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Mary Ann Liebert, Inc.

Fig. 6

DHE (dihydroethidium) fluorescence ($O_2^{\bullet-}$) during perfusion of guinea-pig isolated hearts at 37°C and 17°C with and without four drugs. Cardiac cooling markedly increased $O_2^{\bullet-}$ emission. MnTBAP, a SOD mimetic, reduced $O_2^{\bullet-}$ emission, and menadione (vitamin K_3), an electron-transport inhibitor, increased $O_2^{\bullet-}$ emission, whereas BDM (butanedione monoxime), a contractile inhibitor, and L-NAME (N^G -nitro-L-arginine methyl ester), an inhibitor of NO^* synthesis, had no effect on $O_2^{\bullet-}$ emission. DHE is thought to react with $O_2^{\bullet-}$ to form 2-OH-E⁺, which produces a transient red spectral shift. [Reprinted with permission from Camara *et al.* (71)].




Fig. 7

Dityrosine (diTyr) fluorescence (ONOO^-) during perfusion of guinea-pig isolated hearts at 37°C and 17°C with and without four drugs.

Cardiac cooling markedly increased ONOO^- . MnTBAP, a SOD mimetic, and L-NAME (*N*^G-nitro-L-arginine methyl ester), an inhibitor of NO^* synthesis, both reduced ONOO^- , whereas menadione (vitamin K₃), an electron-transport inhibitor, increased ONOO^- , and BDM (butanedione monoxime), a contractile inhibitor, had no effect on ONOO^- . [Reprinted with permission from Camara *et al.* (71)].




Table 2.

Drugs Commonly Used to Assess Deductively the Sites of Electron Leak and Superoxide Generation within the Respiratory Chain

Drug	Mechanism	Effect
<i>Complex I sites</i>	<i>Inhibitors of NADH oxidation</i>	
Rotenone (ROT)	Inhibits transfer of e ⁻ from Q-binding site to complex I	+ O ₂ ^{•-}
Amobarbital (AMO)	Blocks transfer of e ⁻ from Q _{NF} to Q _{NS} distal to N2 Fe/S center	+ O ₂ ^{•-}
Piericidin A (PCA)	Inhibits e ⁻ by competing with Q _B for binding site in complex I	+ O ₂ ^{•-}
<i>Complex II sites</i>	<i>Inhibitors of succinate dehydrogenase</i>	
Malonate (MAL)	Competitive inhibitor of complex II	+ O ₂ ^{•-}
Methylmalonate (MML)	Competitive inhibitor of complex II	+ O ₂ ^{•-}
3-Nitropropionate (3NP)	Irreversible inhibitor of complex II	+ O ₂ ^{•-}
Atpenins (APT)	Noncompetitive inhibitor of complex II	+ O ₂ ^{•-}
<i>Complex III sites</i>	<i>Inhibitors of quinone (Q) cycle</i>	
Stigmatellin (STG)	Prevents transfer of 1 st e ⁻ from QH ₂ to Fe/S protein (ISP)	± O ₂ ^{•-} ^a
Myxothiazol (MYX)	Prevents binding of QH ₂ at Q _o site	+ O ₂ ^{•-}
Antimycin A (ANA)	Prevents transfer of 2 nd e ⁻ to Q ₁ site	+ O ₂ ^{•-}
<i>Complex IV sites</i>	<i>Inhibitors of O₂ binding</i>	
K ⁺ cyanide (KCN)	Allosterically inhibits cytochrome oxidase	± O ₂ ^{•-} ^b
Na ⁺ azide (NaN ₃)	Allosterically inhibits cytochrome oxidase	± O ₂ ^{•-}
Carbon monoxide (CO)	Competes with binding of O ₂ to cytochrome oxidase	± O ₂ ^{•-}
Nitric oxide (NO [•])	Competes with binding of O ₂ to cytochrome oxidase	± O ₂ ^{•-}
	<i>General oxidants</i>	

Drug	Mechanism	Effect
Menadione (vitK ₃)	Stimulates redox cycling by one e ⁻ reductive enzymes	+ O ₂ ^{•-}
Quinones, doxorubicin	Reacts with Fe ³⁺ compounds to produce Fe ²⁺ + e ⁻	+ O ₂ ^{•-}
H ₂ O ₂	Reacts with Fe compounds to produce Fe(IV=O) [•] and Fe ⁺³ + [•] OH + ⁻ OH Fenton effect (minor)	+ [•] OH

Note: Effects of some drugs on O₂^{•-} generation^{a,b} depend on the substrate used and whether other drugs that act on the respiratory system are present.

+, increase; -, decrease.

Fig. 8.

Schema of proposed O₂^{•-} generation sites in complex I at FMN (flavin), Fe-S centers N1–N5, and/or Q binding sites (A–C, circles).

Electron transport can be forward (solid arrow) or reverse (dashed arrow); O₂^{•-} release is into the matrix only. SDH, succinate dehydrogenase. [Used with permission of and modified from Brand *et al.* (48)].




Fig. 9

Model of $O_2^{\cdot-}$ generation during forward (*top*) and reverse (*bottom*) electron transfer within complex I. During forward transport (substrate pyruvate), e^- are passed from NADH to Q in a quinone-reducing site *via* the FMN and Fe-S centers. The resulting QH^{\cdot} is reduced in a ΔpH -dependent generating step to form QH_2 with another e^- from QH_2 or QH^{\cdot} at the quinol oxidation site. $O_2^{\cdot-}$ generation is low unless Q-site inhibitors are present and the ΔpH is large. During reverse transport (substrate succinate), e^- are passed from QH_2 to NAD, so that the pool is reduced to NADH. A large ΔpH drives the formation of QH^{\cdot} , which loses its unpaired e^- to O_2 because all redox centers upstream of Q are fully reduced. [Used with permission of and modified from Lambert and Brand (200)].




Fig. 10

H₂O₂ production is more dependent on mitochondrial Δ pH than on $\Delta\Psi_m$ during reverse electron transfer at complex I. This is suggested by the dependence of H₂O₂ production on $\Delta\Psi_m$ when Δ pH is present (a) or absent (b); the difference (c) represents H₂O₂ production as a function of Δ pH. Δ pH was abolished with nigericin (b), which converts any Δ pH into $\Delta\Psi_m$. [Reprinted with permission from Lambert and Brand (201)].




Fig. 11

Mechanisms of $O_2^{\bullet-}$ formation from complex III. Oxidation of quinol (QH_2) results in transfer of a single e^- to a high-reduction-potential chain at the Q_o (extramatrix) site containing the Fe-S protein (ISP, Rieske protein) and on to cytochrome c_1 and cytochrome c , and finally to cytochrome c oxidase. The remaining QH^{\bullet} is unstable and donates the second e^- to a low-reduction-potential chain consisting of cytochrome b_l (low) and b_h (high), leading the e^- toward the Q_i (matrix) site to form a stable QH^{\bullet} ; this QH^{\bullet} is then reduced to QH_2 by a subsequent e^- passed along the low-reduction-potential chain, thereby completing the $Q-QH_2-Q$ cycle. In (A), antimycin A causes extramatrix release of $O_2^{\bullet-}$; in (B), stigmatellin and myxothiazol block antimycin A from releasing $O_2^{\bullet-}$. [Used with permission of and modified from Andreyev *et al.* (8)].




Fig. 12

Highly reduced and coupled mitochondria (high $\Delta\Psi_m$ and limited respiration due to lack of ADP) leak e^- for attack by O_2 because QH^\bullet is not as rapidly reduced to QH_2 . Progressive uncoupling by using a protonophore (SF6847) gradually reduces $\Delta\Psi_m$ and increases respiration while markedly preventing H_2O_2 generation. A similar effect occurs during state 3 with added ADP. [Reprinted with permission from Korshunov *et al.* ([191](#))].




Fig. 13

Isolated mitochondria can produce H_2O_2 during state 3 (ADP stimulated) as well as during state 4 conditions during forward electron flow, provided that $[O_2]$ and mitochondrial protein concentration are sufficient. [Reprinted with permission from Saborido et al. (276)].




Fig. 14

ROS production at complex I in cardiac mitochondria is critically dependent on a highly reduced NADH pool. Downstream inhibition of electron transfer (respiration) by rotenone leads to reduction of all upstream carriers and results in e^- leak and ROS generation. Note the large decrease in respiration rate and the increasingly reduced redox state with rotenone associated with ROS production during state 3 (*left*) compared with state 4 (*right*). [Reprinted with permission from Kushnareva *et al.* ([199](#))].




Fig. 15

DHE (dihydroethidium) fluorescence ($O_2^{\bullet-}$ emission) increases during perfusion of guinea-pig isolated hearts during intermittent (A) and continuous (B) cooling from 37°C to 2°C. The increase in $O_2^{\bullet-}$ emission with cooling likely results both from increased $O_2^{\bullet-}$ generation and decreased $O_2^{\bullet-}$ -scavenging capability by MnSOD. Afu, arbitrary fluorescence units. [Reprinted with permission from Camara *et al.* (71)].




Fig. 16

Temporal relation between $\Delta\Psi_m$ (TMRM fluorescence) and ROS (DCF fluorescence) in a cardiac myocyte. "Trigger" ROS was induced by photoactivation of TMRM derivatives. Note the burst of ROS after photoexcitation caused a decrease in $\Delta\Psi_m$, which was assumed to be a result of ROS-induced MPT opening. [Reprinted with permission from Zorov *et al.* (336)].




Fig. 17

Averaged mitochondrial $[Ca^{2+}]$ (A), NADH (B), and DHE ($O_2^{\bullet-}$) (C) in four groups of guinea-pig isolated hearts over time. Groups are time control *versus* 30-min global ischemia (isc) at 37°C *versus* 17°C. Note the increases in mitochondrial $[Ca^{2+}]$ and $O_2^{\bullet-}$, while NADH decreases, during later ischemia. Variables were measured in the left ventricle with a trifurcated fiberoptic probe and differential fluorescence spectrophotometry. [Reprinted with permission from Riess *et al.* (269)].




Fig. 18

Averaged DHE ($O_2^{\bullet-}$) (A) and mitochondrial $[Ca^{2+}]$ (B), in five groups of guinea-pig isolated hearts over time. Groups are 30-min global ischemia control and preischemia treatments with MnTBAP, catalase + glutathione (CG), MnTBAP + CG (MCG), and L-NAME. Note that the MnTBAP-treated group exhibited the largest increase in $[Ca^{2+}]$, whereas the MCG-treated group exhibited the smallest increases in $[Ca^{2+}]$ and $O_2^{\bullet-}$. [Reprinted with permission from Camara *et al.* (70)].




Fig. 19

Averaged ETH (DHE) fluorescence ($O_2^{\bullet-}$) in four groups of guinea-pig isolated hearts over time. Note that the increase in $O_2^{\bullet-}$ during brief global ischemia (IPC, ischemic preconditioning) was attenuated by MnTBAP and that MnTBAP also blocked the reduction in $O_2^{\bullet-}$ afforded by IPC so that $O_2^{\bullet-}$ increased to the level of the ischemia control. [Reprinted with permission from the publisher of Kevin *et al.* ([181](#))].




Fig. 20

Dependence of H₂O₂ production during state 3 (A) and state 4 (B) on [O₂] in mitochondria isolated from rat liver. Note that at <5 μM [O₂], H₂O₂ production decreased toward zero. Experiments were conducted in the presence of succinate + rotenone and oligomycin (state 4 only). [Reprinted with permission from Hoffman *et al.* ([161](#))].




Fig. 21

Schema of glutaredoxin and thioredoxin buffering system in the mitochondrion. Glutathione is transported across the outer membrane (OM) *via* porin into the intermembrane space (IMS) and across the inner membrane (IM) *via* a transporter (trans) to the matrix. Other redox proteins are transported *via* the TOM and TIM23 complexes. The glutaredoxin and thioredoxin reactions in the matrix repair oxidatively damaged proteins. [Used with permission and modified from Koehler *et al.* ([189](#))].




Fig. 22

Pathways of reactive O₂ metabolism. O₂^{•-} and H₂O₂ exert protective effects on the cell *via* signaling pathways for preconditioning *via* phosphorylation products and *via* oxidant-induced gene products that activate multiple groups of proteins. Severe hypoxia, ischemia and reperfusion, and toxins can cause excessive oxidant stress that leads to cell-damaging effects of ferryl radicals such as Fe(IV) = O[•]. [Used with permission and modified from Becker (27)].




Fig. 23

Pathways of NO^\bullet , $\text{O}_2^{\bullet-}$, and HO^\bullet and their reactive lipid products, including lipid peroxides (1), 15-deoxy- $\Delta^{12,14}$ -prostaglandin J_2 (2), isoprostane J_2 (3), 4-hydroxynonenal (4-HNE) (4), acrolein (5), nitrolinoleic acid (6), and lysoPC (7). [Used with permission and modified from Zmijewski *et al.* (334)].




Fig. 24

Correlations between mitochondrial H⁺ leak, metabolic rate, and membrane fatty acid polyunsaturation in liver mitochondria.

[Reprinted with permission from Brookes (55)].




Fig. 25

Assessment of proton leak from the downward shift in the $\Delta\Psi_m$ versus respiratory-rate curve after IPC + ischemia versus ischemia alone (IR); no ischemia is control (CON). Note the decrease in respiration after IPC compared with IR at 160 mV (**insert**), indicating less proton leak. Data from rat mitochondria isolated at 30 min of reperfusion after ischemia. [Reprinted with permission from Nadtochiy *et al.* (238)].




Fig. 26

The K⁺ cycle in heart mitochondria. In this model, electrophoretic matrix K⁺ influx (leak) is matched by electrogenic H⁺ efflux (ETS), and K⁺ influx *via* K_{ATP} and K_{ca} channels is matched by K⁺ efflux and H⁺ influx *via* KHE (K⁺/H⁺). The H⁺ influx is accompanied by phosphate influx (P_i); a net uptake of phosphoric acid and salt occurs, so that matrix swelling occurs. Finally, matrix alkalization releases the KHE from allosteric inhibition by protons, and its activity increases to match K⁺ influx. [Used with permission and modified from Costa *et al.* (95)].




Fig. 27

Small increases in $O_2^{\bullet-}$ generation assessed by DHE fluorescence (ETH) in isolated hearts during treatment with the anesthetic sevoflurane (Sevo) (A) were blocked by the SOD mimetic MnTBAP (C, D) but not by the K_{ATP} channel inhibitor 5-HD (B, D). [Reprinted with permission from Kevin *et al.* (182)].




Fig. 28

Proposed effect of submaximal K^+ influx with mBK_{Ca} channel opening (1) on proton leak (2), proton ejection and respiration (3), $\Delta\Psi_m$ (4) and generation of $O_2^{\bullet-}$ and H_2O_2 (5). Net effect of mBK_{Ca} channel opening (B) (vs. closed, A) would be to accelerate electron flux without a change in $\Delta\Psi_m$ due to support by proton leak; maintained $\Delta\Psi_m$ and higher electron flow would accelerate ROS generation. [Reprinted with permission from Heinen *et al.* (159)].




Fig. 29

Mitochondrial H₂O₂ release rate from heart isolated mitochondria. (A) Representative trace for 30 μ M NS-1619-induced increase in cumulative H₂O₂ release with succinate + rotenone as substrate. Maximal ROS production was stimulated in some experiments by adding complex III blocker antimycin A (5 μ M). Catalase (300 U/ml) was added to confirm H₂O₂ production. *Open arrow a*, baseline; *open arrow b*, treatment effect. **(B)** Summary of H₂O₂ release rates. All treatment effects are compared with baseline of the same experiment. [Reprinted with permission from Heinen *et al.* ([159](#))].




Fig. 30

ROS production (Cb_x-DCF fluorescence) in rat-heart mitochondria over time after adding (before time zero) valinomycin (Val), diazoxide (Dzx), and 5-hydroxydecanoate (5-HD) singly or together with ATP to maintain state 4 (A). ROS production was obtained from the initial slopes of traces such as those shown in (A) and plotted as percentage ATP-inhibited control rate obtained in the absence of drug. Adding ROS scavenger *N*-(2-mercaptopropionyl)glycine (MPG) decreased ROS production in the presence of Dzx and Val ~10-fold (B). [Reprinted with permission from Andrukhiv *et al.* (9)].




Fig. 31

Effects of BK_{Ca} channel opener NS1619 on attenuating O₂^{•-} emission (A) and NADH (B) during ischemia and reperfusion in guinea-pig isolated hearts were largely reversed by BK_{Ca} channel blocker paxilline (PX) or by SOD mimetic MnTBAP (TB). **p* < 0.05 vs. Con, NS + PX, NS + TB. [Reprinted with permission from Stowe *et al.* (298)].




Fig. 32

Effect of reversible complex I inhibitor amobarbital on $O_2^{\bullet-}$ generation (DHE fluorescence) (A) and mitochondrial $[Ca^{2+}]$ (B) during ischemia and reperfusion in guinea-pig isolated hearts. Arrow, 1-min amobarbital perfusion immediately before ischemia. **Inset: Effect of amobarbital before ischemia on $O_2^{\bullet-}$ emission and $[Ca^{2+}]$. White and hatched bars, baseline and 1 min of treatment, respectively. [Reprinted with permission from Aldakkak *et al.* (5)].**




Fig. 33

Electrons derived from reducing equivalents are transferred through the respiratory system to complex IV where $4e^-$ are transferred to O_2 . During hypoxia, this transfer is slowed, even though sufficient O_2 exists to function as the electron acceptor. The resulting buildup of electrons and NADH may set up a condition for electron leak to O_2 , partially bypassing complex IV. [Used with permission of and modified from Chandel and Schumacker (80)].




Fig. 34

Effect of H₂O₂ on TCA cycle and products of 2-oxo acid nonenzymatic oxidation on metabolism (A) and signaling (B). (A) Pyruvate (PYR), α-ketoglutarate (KGL), and oxaloacetate (OA) are decarboxylated by H₂O₂ to form acetate, succinate, and malonate (*broken line*) nonenzymatically instead of acetyl-CoA (acCoA), succinyl-CoA (sucCoA), and malate (MAL), or phosphoenolpyruvate (PEP) formed enzymatically (*solid line*) and are used to synthesize fatty acids, cholesterol, and glucose. ROS inhibit the TCA cycle mainly at aconitase and α-ketoglutarate dehydrogenase (KGDH) (*thick arrow*). The truncated Krebs cycle instead of the omitted steps of citric acid (citrate, CIT; cis-aconitate, cAC; isocitrate, ISC) is closed by transamination of OA with glutamate (GLU), which leads to formation of KGL and aspartate (ASP). As a part of the malate/aspartate shunt, these substrates enter the cytosol where OA is formed by transaminase from ASP or citrate lyase from citrate. (B) HIF-1α degrades in cells at normal O₂ levels after prolyl residue hydroxylation by O₂/KGL/Fe(II)-dependent hydroxylase. Hypoxia, succinate, and KGL decarboxylation by H₂O₂, which leads to decreased KGL and increased succinate, inhibits the enzyme, permitting transport of HIF-1α to the nucleus and HIF-dependent transcription of a wide variety of genes responsible for O₂ transport, vascularization, and anaerobic energy production. [Used with permission of and modified from Fedotcheva *et al.* (121)].

